A comparison of clinical and cardiac biomarker profiles of patients with community-acquired pneumonia and with COVID-19 pneumonia in a high HIV prevalence adult population. Running title: Comparison of patients with CAP and COVID-19 pneumonia

A comparison of clinical and cardiac biomarker profiles of patients with community-acquired pneumonia and with COVID-19 pneumonia in a high HIV prevalence adult population. Running title: Comparison of patients with CAP and COVID-19 pneumonia | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article A comparison of clinical and cardiac biomarker profiles of patients with community-acquired pneumonia and with COVID-19 pneumonia in a high HIV prevalence adult population. Running title: Comparison of patients with CAP and COVID-19 pneumonia Murimisi Mukansi, Helen C. Steel, Theresa M. Rossouw, Ismail Kalla, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7376744/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Introduction There are no studies from sub-Saharan Africa comparing patients with community-acquired pneumonia (CAP) and those with COVID-19 pneumonia, which is what was undertaken in this study. Methods Consecutive adult patients hospitalized with CAP (n=59), or COVID-19 pneumonia (n=74) were compared with regard to co-morbidities, HIV status, routine laboratory parameters, and levels of systemic inflammatory and cardiac biomarkers. Results There were an equal number of males and females, but CAP patients were younger. Human immunodeficiency virus infection was more common in CAP patients, whereas other comorbidities were more prevalent in COVID-19 pneumonia. CAP patients had more cough, fever, greater tachycardia, and lower blood pressure, while dyspnoea, tachypnoea, and respiratory alkalosis were more prevalent in COVID-19. Several routine laboratory parameters differed. Cardiovascular biomarkers were mostly elevated in both groups compared to controls. However, levels of creatinine kinase-MB (CK-MB) and cardiac troponin I were significantly elevated in COVID-19 versus CAP patients. When compared by HIV status no difference in the cardiac biomarker levels was seen in CAP patients with and without HIV, but significantly higher levels were noted in the HIV-positive COVID-19 group. Conclusion Cardiac biomarker analysis suggests that HIV-infected patients with COVID-19 pneumonia may be at greatest risk of cardiovascular events. cardiac biomarkers cardiovascular events community-acquired pneumonia co-morbidities COVID-19 pneumonia HIV Figures Figure 1 Introduction Community-acquired pneumonia (CAP) and COVID-19 pneumonia are multisystem diseases with the respiratory tract as the port of entry. Cardiovascular events (CVEs) have been documented to occur in patients with CAP and, more recently, in cases with COVID-19 pneumonia, and these events represent one of the major extrapulmonary manifestations, which contribute to the mortality and morbidity of patients with these infections. These CVEs develop in up to a quarter of cases, contributing considerably to both short- and long-term cardiac dysfunction.[ 1 – 3 ] These CVEs may occur at the time of diagnosis of pneumonia, or during convalescence,[ 1 – 3 ] and are evident either in patients with underlying cardiac disease or cardiovascular risk factors, as well as in those without known cardiovascular risk.[ 4 , 5 ] Notably, cardiovascular diseases represent risk factors for both CAP and COVID-19, consistent with a bidirectional relationship.[ 6 – 10 ] The pathophysiology of the CVEs involves both pathogen-mediated and/or host-mediated myocardial damage.[ 1 , 11 ] The host-mediated events are related to the systemic inflammatory/immune response to these infections by mechanisms that are not fully elucidated.[ 3 , 12 ] In approximately 20–30% of COVID-19 cases, myocardial injury is indicated by elevated levels of N-terminal pro-B-type natriuretic peptide (N-Pro BNP) and cardiac troponin I (cTnI) isoenzymes and are indicative of major CVEs.[ 13 , 14 ] It is difficult to differentiate between CAP and COVID-19 pneumonia on the basis of clinical symptoms and signs alone, as both have similar features. Furthermore, SARS-CoV-2 infection continues to present major clinical, diagnostic, and therapeutic challenges. Some 20% of patients with SARS-CoV-2 infection may develop severe complications, including COVID-19 pneumonia.[ 15 – 17 ] Notably the clinical and radiological features of patients with COVID-19 pneumonia are very similar to those of CAP, irrespective of bacterial or viral aetiology, which also frequently occurred concomitantly during the pandemic.[ 18 ] Clearly, there is a need to differentiate between the two types of infection because they need different forms of management and therapy.[ 19 ] Furthermore, in addition to occurring in patients with CAP, cardiovascular complications were noted to occur in patients with COVID-19 from very early on in the pandemic.[ 18 ] These findings also suggest that the early detection, treatment and prevention of cardiovascular events will likely contribute to an improved outcome in both CAP and COVID-19 pneumonia.[ 20 , 21 ] While the treatment of CAP is clearly outlined in most guidelines, that of COVID-19 pneumonia is still under development.[ 22 , 23 ] Several studies have been undertaken to compare clinical, laboratory and CVEs internationally; however, there are no data from sub-Saharan Africa, among patients with a high prevalence of human immunodeficiency virus (HIV)-infection.[ 19 , 24 – 28 ] Given the propensity of patients with CAP and COVID-19 pneumonia to develop CVEs, it is somewhat surprising that few studies have been undertaken to compare the clinical and biomarker profiles of patients with these two infections and to identify differences that may exist with regard to occurrence of these events, particularly in a low-middle income country with a considerable HIV prevalence. Accordingly, the purpose of the current study was to investigate and compare demographic, clinical and routine laboratory characteristics, as well as systemic inflammatory and cardiovascular biomarker profiles in patients with CAP or COVID-19 pneumonia. Patients and methods Study population This was a prospective study conducted at two centres, namely the Helen Joseph Hospital (University of the Witwatersrand, Johannesburg, RSA), which enrolled CAP patients in the pre-COVID-19 era, and the Steve Biko Academic Hospital (University of Pretoria, Pretoria, RSA), which recruited patients with COVID-19 pneumonia. The study enrolled CAP cases between August 2019 and March 2020 and COVID-19 cases between March and June 2021. Cases enrolled (n = 133) were consecutive adult patients ≥ 18 years old, hospitalized with either CAP (n = 59) or COVID-19 pneumonia (n = 74). A control group (n = 15) comprising healthy, HIV-uninfected individuals was included in the study. The study components were approved by the appropriate Human Research Ethics Committees (University of the Witwatersrand: reference M180382; and University of Pretoria: reference 247/2020). Written informed consent was obtained from all participants before the commencement of the study. The diagnosis of pneumonia was based on clinical signs and symptoms (cough, sputum expectoration, pleuritic chest pain, dyspnoea, and/or fever) and a radiologically-confirmed pulmonary infiltrate. Immunosuppressed individuals were included. The exclusion criteria were: 1) nosocomial infection, occurring more than 48 hours after admission and/or hospitalization in the preceding 90 days; 2) children below 18 years of age; and 3) aspiration pneumonitis. SARS-CoV-2 infection was confirmed using a polymerase chain reaction (PCR) test on nasopharyngeal swabs, in accordance with the recommendations of the National Institute for Communicable Diseases, Johannesburg, RSA.[ 29 ] The CAP patients presented before the pandemic, prior to the availability of tests for SARS-CoV-2, so no tests to rule out COVID-19 were done or indicated in that group. The severity of CAP was based on the CURB-65 score (a 5-point severity of illness score).[ 30 ] while that of COVID-19 pneumonia was based on the WHO severity score. These scores subdivided COVID-19 into mild, moderate, and severe or critical.[ 31 ] A detailed medical history and examination were obtained on admission for all enrolled patients, including current symptoms and duration, as well as previous illnesses and data on relevant chronic medication. Laboratory testing Routine laboratory testing was done as part of standard of care, including full blood count, urea and electrolytes, C-reactive protein (CRP) and procalcitonin (PCT). Samples were processed at the National Health Laboratory Services, Johannesburg, RSA. In addition, levels of study-specific biomarkers , B-natriuretic peptide (BNP), creatine kinase-MB (CK-MB), endocan-1, NT-pro BNP and troponin I were measured using a Milliplex® MAP Human Cardiovascular Disease panel (Merck, DE). The biomarkers were analysed using a Bio-Plex suspension array platform (Bio-Rad, Hercules, CA, USA). All methods were followed as outlined by the manufacturers. These assays were undertaken at the Department of Immunology, University of Pretoria. For measurement of cardiac and inflammatory biomarkers, plasma was processed and stored at -80 ºC prior to analysis. Statistical analyses Statistical analyses were performed using Stata 17 (Stata Statistical Software: Release 17. StataCorp LLC, College Station, TX). Data were expressed as mean ± standard deviation (SD) for parametric parameters and median ± interquartile range (IQR) for the parameters with a non-Gaussian distribution. Categorical/binary values are presented as counts and percentages with comparisons performed by means of the Pearson’s chi-square or Fisher’s exact tests. Comparisons of continuous variables were made using the parametric tests (paired and unpaired Student’s t-test) and non-parametric tests (Kruskal-Wallis test with the post-hoc Dunn test for unpaired samples and the Wilcoxon sign-rank test for paired samples), with p-values ≤ 0.05 considered statistically significant. Given the relatively small sample size and the large number of predictor variables, formal regression analysis was not undertaken. Limited regression analysis for the different sets of variables was, however, conducted to support the results of the univariate analysis. All predictor variables that were significant in the univariate analysis were transformed, if necessary, and entered in the multivariable logistic regression analysis in a stepwise backwards manner. Variables with multicollinearity were removed. An inflammation score was calculated based on the work of Zhu et al .[ 32 ] Briefly, the score is composed of four serum and cellular circulating inflammatory markers, namely CRP, WBC, platelet count, and granulocyte-to-lymphocyte ratio. Each value is calculated based on 10 tiles of each biomarker level. The highest (7–10) and lowest (1–4) deciles are scored as positive and negative from 1 to 4, respectively, and deciles 5–6 are scored as zero. The total score is the sum of the four biomarkers and ranges from − 16 to 16. Spearman’s correlation with Bonferroni correction for multiple comparisons was performed for clinical and laboratory variables of interest. Given HIV- and sex-related differences in CAP and COVID-19 mortality,[ 33 , 34 ] additional comparisons were made between patients with and without HIV infection and those patients who identified as male and female, respectively. These analyses were performed in the two groups combined , as well as in the CAP and COVID-19 groups separately. Results Table 1 shows the demographic information, underlying co-morbid conditions, and clinical findings of the patients with CAP and those with COVID-19 pneumonia at initial presentation. Patients with CAP were significantly younger than patients with COVID-19. Among the co-morbidities, the frequency of HIV-positivity was significantly higher in patients with CAP compared to those with COVID-19 pneumonia (45.8% versus [vs] 32.4%; p=0.032). In contrast, the frequencies of neoplastic diseases, chronic heart disease, diabetes mellitus, chronic obstructive airway disease , hypertension, and coronary artery disease were significantly higher in the COVID-19 group. Use of pharmacological agents, such as beta-blockers and angiotensin-converting enzyme inhibitors (ACEI), was significantly higher in patients with COVID-19 pneumonia (4.1% vs 1.7% and 4.1% vs 3.4%, respectively; p<0.001 for both agents), reflecting the higher prevalence of co-morbid disease in this group. Patients with COVID-19 pneumonia had a longer duration of respiratory symptoms at presentation and were more likely to have dyspnoea than patients with CAP. In contrast, cough and fever were significantly more common in the CAP group. The systolic and diastolic blood pressure, as well as the respiratory rate were lower, while the heart rate was higher in patients admitted with CAP. Table 1: Demographics, co-morbidities and clinical characteristics of patients with CAP versus COVID-19 pneumonia. CAP (n=59) COVID-19 pneumonia (n=74) p - value Demographic information Age (years) (mean ± SD) 44.3 (± 13.3) 53.1 (± 13.1) <0.001 Gender 27 males: 32 females 36 males: 38 females 0.811 Co-morbidities [n (%)] HIV 27 (45.8) 24 (32.4) 0.032 Neoplastic disease 0 (0) 3 (4.1) 0.021 Chronic kidney disease 1 (1.7) 4 (5.4) 0.065 Chronic heart disease 1 (1.7) 8 (10.8) 0.001 Diabetes mellitus 5 (8.5) 20 (27.0) <0.001 COPD 1 (1.7) 5 (6.8) 0.005 Hypertension 4 (6.8) 27 (36.5) <0.001 Symptoms Number of days symptomatic 5 (3 – 6) 7 (5 – 9) 0.001 Cough 56/56 (100%) 43/54 (79.6%) <0.001 Fever 27/56 (48.2%) 21/54 (38.9%) <0.001 Dyspnoea 29/56 (51.8%) 45/54 (83.3%) <0.001 Sputum expectoration 36/56 (64.3%) Not recorded Clinical Features Systolic BP (mmHg) 112.5 (98.5 – 131) 126 (117 – 139) 0.003 Diastolic BP (mmHg) 67.5 (55.5 – 82.5) 79 (69 – 86) 0.002 Respiratory rate (breaths/min) 22 (19 – 24) 26 (22 – 30) 0.002 Heart rate (beats/min) 112 (103 – 127) 100 (90 – 109.5) <0.001 * Maximum creatinine clearance was taken as 60 mL/min. Results are reported as median (interquartile range) unless indicated otherwise. Values in bold denote significance. Abbreviations: BP: Blood pressure; CAP: community-acquired pneumonia; COPD: Chronic obstructive pulmonary disease; COVID-19: COVID-19 pneumonia; HIV: Human immunodeficiency virus. The CAP patients generally had mild or moderate disease. Only three (5%) patients had severe disease according to the CURB-65 score (CURB-65 >3). Of the COVID-19 patients, 13/61 (21.3%) with disease severity recorded, had severe disease. This was significantly more than the CAP patients presenting with the equivalent CURB-65 score (21.3% vs 5%; p=0.014). In multivariable regression analysis, the clinical symptoms of less dyspnoea and fewer symptomatic days, together with a higher heart rate, distinguished patients with CAP from those with COVID-19 pneumonia (Supplementary Table 1). Table 2: Routine laboratory parameters of patients with CAP versus COVID-19 pneumonia. Laboratory parameters CAP (n=59) COVID-19 pneumonia (n=74) p-value Arterial blood gas pH 7.43 (7.38 – 7.47) 7.47 (7.42 – 7.51) 0.004 SpO 2 78.25 (66.05 – 94.5) 93 (90 – 96) <0.001 HCO 3- 21.15 (20 – 23.8) 20 (18 – 22.5) 0.027 Lactate 2 (1.3 – 2.9) 1.35 (0.9 – 1.7) 0.004 PaO 2 /FiO 2 199 (149 – 280) 183.2 (104.4 – 391.7) 0.236 HIV CD4 + T-cell count (cells/mm 3 ) 197 (156 – 298.5) 212 (117 – 296) 0.381 HIV viral load (copies/mL) 1,850 (69.5 – 81,500) 20 (20 – 12,738) 0.006 Haematology WBC 13.48 (9.20 – 18.99) 8.54 (6.85 – 10.86) <0.001 PMN 11.46 (6.23 – 17.02) 7.32 (5.29 – 9.55) 0.040 Lymphocytes 1.44 (1.04 – 1.93) 1.11 (0.75 – 1.50) 0.072 PMN/lymphocyte ratio 6.78 (4.07 – 11.9) 6.84 (4.27 – 10.74) 0.490 Platelets 262.5 (192.5 – 313.5) 261.5 (184 – 352) 0.362 Platelet/lymphocyte ratio 151 (80 – 238) 277 (162 – 382) 0.010 Inflammatory biomarkers CRP 235.5 (109 – 310) 113 (69.5 – 215.5) 0.004 PCT 0.81 (0.68 – 62.03) 0.09 (0.04 – 0.40) 0.003 Urea and electrolytes Na + (mean ± SD) 134 ±5 136 ±3.8 0.027 K + 4.0 (3.5 – 4.5) 4.4 (4.0 – 5.1) <0.001 BUN 5.6 (3.8 – 9.7) 5.3 (3.7 – 8.0) 0.263 Creatinine 86 (64 – 124) 71 (59 – 95) 0.032 Creatinine clearance* (mL/min) 60 (42 – 60) 60 (60 – 60) <0.001 HbA1c 6.1 (5.7 – 7.2) 6.3 (5.8 – 7.7) 0.333 Liver function AST 46 (27 – 104) 39 (24 – 61) 0.126 ALT 45 (27 – 72) 28 (18 – 47) 0.011 ALP 83 (64 – 119) 81 (68 – 116) 0.381 GGT 53.5 (28 – 99) 71 (42 – 133) 0.069 * Maximum creatinine clearance was taken as 60 mL/min. Results are reported as median (interquartile range) unless indicated otherwise. Values in bold denote significance. Abbreviations: ALP: Alkaline phosphatase; ALT: Alanine transaminase; AST: Aspartate transaminase; BUN: Blood urea nitrogen; CRP: C-reactive protein; CD4: Cluster of differentiation 4; FiO 2 : fraction of inspired oxygen; GGT: gamma-glutaryl transaminase; HCO 3 : bicarbonate; HIV: Human immunodeficiency virus; K + : potassium; Na + : Sodium; PaO 2 : Partial pressure of oxygen; PCT: Procalcitonin; PMN: Polymorphonuclear cells; SpO 2 : peripheral oxygen saturation; WBC: white blood cells. There were several significant differences in the routine laboratory parameters between the two groups, with important highlighted differences being a lower peripheral oxygen saturation (SpO 2 ), but higher creatinine, white cell count, CRP and PCT in the CAP group, compared with the COVID-19 group (Table 2). As is evident from Table 2, patients with CAP and HIV (with an HIV viral load [VL] available), had significantly higher VLs than the patients with COVID-19 pneumonia and HIV. Significantly more patients admitted with CAP had a detectable VL i.e. > 50 copies/mL (CAP 13/16 vs COVID-19 10/24; p=0.014) and numerically more had levels above 1,000 copies/mL (CAP 10/16 vs COVID-19 7/24; p=0.053) and 100,000 copies/mL (CAP 4/16 vs COVID 1/24; p=0.073), although the latter two differences did not reach statistical significance. The difference in VL suggests that CAP might have been the presenting clinical presentation in these patients. In the regression model, PCT predicted the data perfectly. A log-transformed value of PCT of £ 2.087 predicted the outcome (CAP vs COVID-19) with 100% accuracy, precluding its inclusion in the multivariable model. Among the remaining variables, a low SpO 2 and creatinine clearance, together with a high CRP differentiated CAP the best from COVID-19 pneumonia (Supplementary Table 2). The inflammatory score was calculated for both groups. The CAP group (n=10) had a mean score of 0 (SD ±6.36) with a lowest score of -7 and a highest score of 10. The COVID-19 group (n=44) had a mean score of -0.39 (SD ±6.16) with a lowest score of -16 and a highest score of 11. The inflammatory score correlated well with the WHO COVID-19 severity score: Mild disease had a mean of -6.25 (SD ±8.66); moderate disease had a mean of -0.56 (SD ±5.58) and severe disease had a mean of 2.5 (SD 5.84). Due to the small number of CAP patients with all variables recorded, further analysis was not conducted. Table 3. Comparison of cardiovascular biomarkers in participants with CAP, COVID-19, and healthy control individuals. Biomarkers CAP (n=59) COVID-19 (n=74) Controls (n=15) CAP vs COVID CAP vs Controls COVID vs Controls BNP 78.26 (54.74-109.10) 63.89 (63.89-116.21) 75.41 (57.87-91.60) 0.377 0.4702 0.388 NT-pro BNP 219.47 (157.95-496.29) 232.08 (155.39-401.96) 128.56 (34.29-186.89) 0.466 <0.001 <0.001 CK-MB 3,023.57 (1741.37-7037.52) 4,316.19 (2805.97-8115.60) 2,239.70 (712.44-4 215.44) 0.028 0.038 0.001 Troponin-I 109.94 (68.59-335.6) 377.38 (190.35-879.03) 129.77 (88.75-232.97) <0.001 0.310 0.001 Endocan-1 1,735.86 (988.60-2522.52) 2,354.55 (963.00-3716.34) 368.45 (19.45-812.69) 0.123 <0.001 <0.001 Results are reported as pg/mL Values in bold denote significance. Abbreviations: BNP: brain natriuretic peptide; CKMB: Creatine kinase-myoglobin binding; NT-pro BNP: N-terminal pro-brain natriuretic peptide. Table 3 shows a univariate comparison of the cardiac biomarkers in patients with CAP, COVID-19 pneumonia, and healthy control individuals. NT-pro-BNP, CK-MB, and endocan-1 were significantly higher in patients with CAP compared to the control group. Results were similar for those with COVID-19 pneumonia, except that troponin I, in addition, was also higher than the control group. Both CK-MB and troponin I were significantly higher in patients with COVID-19 pneumonia than in those with CAP. Abbreviations: BNP: brain natriuretic peptide; CAP: community-acquired pneumonia; CKMB: Creatine kinase-myoglobin binding; COVID-19: coronavirus disease 2019; NT-pro BNP: N-terminal pro-brain natriuretic peptide. Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4. Differences were also evident between the CAP and COVID-19 groups when the cardiac markers were divided into quartiles (Figure 1). Patients with CAP were significantly more likely to be in the first and third quartile of BNP; in the first quartile of troponin I; and numerically, but non-significantly, in the first quartile of CK-MB. In contrast, patients with COVID-19 pneumonia were more likely to be in the fourth quartile of all the cardiac biomarkers, significantly so in the case of BNP and troponin I. Regression analysis showed that troponin I was the best discriminator between CAP and COVID-19 pneumonia (Supplementary Table 3). Table 4 Gender analysis for CAP and COVID-19 pneumonia cases combined. Biomarkers Male (n=63) Female (n=69) P-value BNP 63.89 (54.74 – 91.76) 81.00 (54.74 – 118.62) 0.055 NT-pro BNP 203.85 (139.11 – 424.22) 253.03 (168.17 – 424.90) 0.173 CK-MB 3,414.84 (1 973.84 – 7 148.17) 3,791.43 (2 322.82 – 9 295.14) 0.171 Troponin I 190.35 (68.59 – 514.39) 321.68 (119.94 – 879.03) 0.024 Endocan-1 1,588.82 (731.94 – 3 136.50) 2,054.73 (1 295.80 – 3 460.84) 0.034 Results are reported as pg/mL. Values in bold denote significance. Abbreviations: BNP: brain natriuretic peptide; CK-MB: Creatine kinase-myoglobin binding; NT-pro BNP: N-terminal pro-brain natriuretic peptide. Sub-analysis of sex within the CAP and COVID-19 groups combined revealed significantly higher levels of troponin I and endocan-1 in women (Table 4). In the individual groups, no significant differences were seen between the two sexeswith CAP, while in the COVID-19 group, troponin I was significantly higher in women (p=0.005) (Supplementary Table 4). Table 5. Correlations matrix Abbreviations: ALT: alanine transaminase; BNP: brain-type natriuretic peptide; CK-MB: creatinine kinase-myoglobin binding; CRP: C-reactive protein; HCO3: bicarbonate; K: potassium; Na: sodium; NT-pro BNP: N-terminal prohormone of brain natriuretic peptide; PCT: procalcitonin; PMN: polymorphonuclear leukocyte count; PLR: platelet lymphocyte ratio; SpO2: peripheral oxygen saturation; WBC: white blood cell count. Annotations: Red indicates negative, and blue indicates positive correlations, with the shades indicating the strength of the correlation. The numbers in bold indicate significance. There were no significant differences between people with and without HIV when comparing the total pneumonia population. Sub-analysis of the two pneumonia groups separately demonstrated no differences in patients with CAP with and without HIV infection (Supplementary Table 5). In contrast, patients with SARS-CoV-2-HIV coinfection had significantly higher levels of BNP (p=0.009), troponin I (p=0.016), and endocan-1 (p=0.019), and non-significantly higher levels of NT-proBNP (p=0.077) than patients with COVID-19 and without HIV (Supplementary Table 5). No significant associations were detected between the cardiac markers of people with HIV infection and either CD4+ T-cell count or VL. With regard to the various correlations, there were significant positive correlations between some of the cardiac biomarkers, in particular BNP and NT-proBNP with each other, and with troponin I. Of the remaining variables there were also positive correlations between the following variables: Age with heart rate; SpO 2 with both heart rate and serum sodium; pH with HCO 3 ; and white blood cell count with creatinine (range of rho values: 0.61-0.70; corresponding range of p values: 0.049-0.018). On the contrary, the following variables showed significant negative correlations, Age with SpO 2 and troponin I; diastolic blood pressure with lactate; heart rate with SpO 2 , CK-MB and troponin I; pH with serum potassium; platelet lymphocyte ratio with BNP, NT-proBNP and troponin I; CRP with troponin I; PCT with serum sodium; and ALT with CKMB (range of rho values: -0.62-0.83; corresponding range of p values: 0.041-0.003) (Table 5. Correlations matrix). While systemic and cardiac biomarkers were measured in both groups, no patients were documented to have had any clinically apparent CVEs. In addition, only one patient in the CAP group died and none in the COVID-19 pneumonia group. Therefore, the association of the biomarkers with the occurrence of CVE or mortality could not be evaluated. Discussion The main findings of this study were that several features distinguishedpatients with CAP from those withCOVID-19pneumonia , includingdemographics, comorbidities, signs and symptoms, routine laboratory parametersas well as cardiac biomarkers. These included a younger age of the CAP cohort, more comorbidities in the COVID-19 cohort aside from HIV, which was more common in the CAP cases, a higher duration of respiratory symptoms prior to hospital presentation in the COVID-19 patients, with dyspnoea being more common, but lower peripheral oxygen saturation, higher WBC count, CRP and PCT, as well as a lower creatinine clearance in the CAP group. There were raised cardiac biomarkers in both pneumonia groups compared to the control cohort, while CK - MB and troponin I were higher in the COVID-19 cases than in the CAP cases. Age CAP patients were younger and were more commonly HIV-infected than the COVID-19 pneumonia cases who were older and had more general co-morbidities other than HIV. This differs from the findings in an Italian study, which indicated non-COVID-19 patients as being relatively older with significant co-morbidities.[35]Furthermore, COVID-19 has been observed to be highly prevalent, particularly severe , and potentially lethal in the elderly population.[36]These differences may be due to an association between the socioeconomic development levels of different countries, as well as the population age gap, with age also related to severity of illness and mortality.[37–40] Co-morbidities The literature confirms the finding that a global increase in morbidity and mortality occurs in patients withCOVID-19 with comorbidities when compared with those without.[41–43]Hypertension, diabetes mellitus, and chronic heart disease areamongthe most prevalent co-morbidities, similar to those indicated in Table1 of the current study.[44] The increase in the risk of SARS-CoV-2 infection is doubled in cases of multimorbidity.[44]In CAP, similarly, there is anassociated increase in the incidence of the disease and also worse outcomes of pneumonia.[45]The VL was significantly elevated in the CAP group compared to the COVID-19 group of patients (Table 2). The difference in VL suggests that CAP might have been the presenting clinical presentation in these patients. Previous studies have documented an increased risk of CAP in patients with poorly controlled HIV, while the relationship documented in patients with HIV and COVID-19 includes both severity of COVID-19 and mortality.[46–48] Signs and symptoms. The duration of symptoms in this cohort was significantly longer in COVID-19 pneumonia patients compared to the CAP patients, confirming the findings of Zhao et al. [49] However, cough and fever were more frequent in the CAP group, as opposed to dyspnoea, which was more significant in the COVID-19 cohort. In the study by Zhao et al . [27] , the symptoms were similar between the two groups, which is also in contrast to Chen et al. , who observed that fever and cough were more common in their patients with COVID-19than in those with CAP.[27,50] Blood gas analysis On admission, arterial blood gas analysis showed significantly different abnormalities between the COVID-19 group compared to the CAP group. The need for oxygen was more evident in the CAP group compared with the COVID-19 group. There was significant respiratory alkalosis, with compensation as evidenced by elevated pH, and lower bicarbonate, in the COVID-19 group of patients. These observations are corroborated in many studies where the blood acid-base status ranges from respiratory to metabolic acidosis or alkalosis, although with respiratory alkalosis in the majority of these.[51–53]Various pathophysiological mechanisms are involved including fever, dysregulation of the renin-angiotensin system, multi-organ inflammation, thrombogenesis, respiratory tract infections and carotid body suppression, with the predominance of each contributing to underlying acid-base shift at different stages of COVID-19.[51–55] Laboratory parameters The CAP group had significantly higher leukocyte counts, as well as levels of CRP and PCT, possibly underscoring the differences between bacterial and viral infections. The trend of the first three parameters is in keeping with observations described in the international literature, with the elevation of these inflammatory markers pointing towards a greater severity of infection.[56–58] However, in the study by Zhao et al ., there was no significant difference in these biomarkers between the SARS-CoV-2-seronegative and -seropositive patients with pneumonia.[27] Furthermore, lactate was significantly higher in patients with CAP compared to the COVID-19 group. This is corroborated by several authors.[59,60] Unlike in CAP, lactate remains near-normal amongst patients with COVID-19 despite an elevated lactate dehydrogenase. It is likely that mitochondrial function is preserved in SARS-CoV-2 infection, despite a hyperinflammatory state, unlike in non-COVID-19 CAP.[59,61] Creatinine clearance was lower in the patients with CAP patients compared to those with COVID-19 pneumonia. Renal dysfunction is a sign of pneumonia progression in both CAP and COVID-19 patients, as indicated in several studies.[62–75] These studies describe high blood urea nitrogen and serum creatinine levels as markers of renal dysfunction. Furthermore, there is a glomerular filtration rate reduction, usually measured by laboratory creatinine clearance. In addition, in severe COVID-19, the elevation of serum creatinine is associated with an increased number of leukocytes, low levels of lymphocytes and platelets, as well as coagulopathy.[74,76–78] Cardiovascular biomarkers Cardiac biomarkers were mostly elevated in both CAP and COVID-19 cases relative to the control group (Table 3). However, a comparison between the CAP and COVID-19 groups revealed that the levels of CK-MB and cardiac troponin I were significantly elevated in COVID-19 pneumonia as compared to CAP (Table 3). This contention was confirmed by the data shown in Figure 1. The literature corroborates this observation.[79–81]Furthermore , when analysing the data comparing HIV-positive versus - negative cases, there were no differences in the cardiac biomarker levels in the CAP group, but notable differences in the COVID-19 group, which attained statistical significance for BNP, troponin I and endocan-1, with trends toward significance in NT-pro-BNP and CK - MB. These findings are in agreement with previous studies suggesting that patients with COVID-19 have a greater propensity to develop cardiac injury compared to a non-COVID-19 pneumonia group.[82,83] and particularly, with respect to the current study, among patients living with HIV. This is compatible with the known effects of HIV infection on the risk of cardiovascular disease. These excess cardiovascular risks persist despite the advent of the modern anti-retroviral therapy era. (85–87 The mechanism of this association between HIV infectivity and elevated cardiac biomarkers in COVID-19, which to the best of our knowledge has not been documented previously, requires further elucidation. Potential limitations As far as we are aware, this is the first study in sub-Saharan Africa to compare the characteristics of patients with CAP and those with COVID-19 pneumonia, and to describe the systemic inflammatory and cardiac biomarker differences between the two groups, both in the presence and absence of concurrent HIV infection. The findings of the current study will add further to the few global studies, which have compared clinical and laboratory parameters between these two groups. [19,24,28,34,57,87–89] However, this study also has some potential limitations. Firstly, it was conducted in only two institutions, so the findings may not be generalizable to the rest of sub-Saharan Africa or even South Africa. Secondly, while systemic inflammatory and cardiac biomarkers were measured in both groups, there was no systematic evaluation for the presence of clinically apparent CVEs, although it appears that none of the primary doctors looking after the patients were alerted to the risk of their development or appeared to be concerned about such events. Thirdly, data were not collected on antiretroviral therapy in the CAP group, so unfortunately, we were not able to determine the possible impact of antiretroviral therapy on any of the findings, particularly the changes in cardiac biomarkers. Fourthly, there was a lack of severe infections in both groups, so a comparison of characteristics in the context of severe versus mild-to-moderate disease was not possible, and only a single mortality was recorded in the CAP group, making it impossible to determine features associated with mortality. Fifthly, there was no long-term follow-up of the patients to allow evaluation of the occurrence of longer-term CVEs and associated cardiovascular biomarker level changes in either of our study groups. Lastly, since only in-hospital patients were recruited, the results cannot be extrapolated to out-patients. Conclusion There were a number of differences in demographic, routine laboratory parameters, as well as systemic inflammatory and cardiovascular biomarkers when comparing patients with CAP and patients with COVID-19 pneumonia. The systemic inflammatory response appeared to be more pronounced in patients with CAP. However, while cardiac biomarkers were raised in both patients with CAP and COVID-19 pneumonia compared to control individuals, this was more so in the latter group, and especially in those who were HIV-positive. Based on the cardiac biomarker analysis, patients with COVID-19 pneumonia who are living with HIV would appear to be at greater risk of developing CVEs, or possibly exacerbations of pre-existing cardiac conditions, than patients with CAP. Declarations Ethics approval and consent : Approved by the Human Research Ethics Committees of the University of the Witwatersrand (Ref: M180382) and University of Pretoria (Ref: 247/2020). Written informed consent obtained from all participants. Acknowledgements: Not applicable. Declaration of competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper . Author contributions: MM, TR, RA, and CF, were responsible for the conceptualisation of the study. MM, HCS, and TMR, were involved in data curation. MM, HCS, TMR, RA and CF accessed and verified the data. TMR and NM undertook the statistical analysis. MM wrote the first draft of the manuscript. MM, HCS, TMR, MN, IK, CM, RA, and CF edited and reviewed the manuscript several times. All authors have seen and approved the final manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Data statement: Data will be made available upon reasonable request. Funding sources: 1. Department of Internal Medicine, RINC funding, Faculty of Health Sciences, University of the Witwatersrand. 2. Discovery Foundation PhD Scholarship Award, Discovery Health (PTY)LTD Consent for publication: Not applicable. References Chakafana G, Mutithu D, Hoevelmann J, Ntusi N, Sliwa K. Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot. Clin Res Cardiol. 2020;109:1460–8. Desai A, Aliberti S, Amati F, Stainer A, Voza A. Cardiovascular Complications in Community-Acquired Pneumonia. Microorganisms. 2022;10(11):2177. Stotts C, Corrales-Medina VF, Rayner KJ. Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities. Circ Res. 2023;132:751–74. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5:831–40. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83–92. Cenko E, Badimon L, Bugiardini R, Claeys MJ, De Luca G, De Wit C, et al. Cardiovascular disease and COVID-19: A consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovasc Res. 2021;117:2705–29. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. Int J Infect Dis. 2013;17(12):e1125–9. Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182–7. Gluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717–56. Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med. 2017;196(5):609–20. Feldman C, Anderson R. Community-acquired pneumonia: Pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148(2):523–32. Shao HH, Yin RX. Pathogenic mechanisms of cardiovascular damage in COVID-19. Mol Med. 2024;30. Zheng KI, Feng G, Liu WY, Targher G, Byrne CD, Zheng MH. Extrapulmonary complications of COVID-19: A multisystem disease? J Med Virol. 2021;93:323–35. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. Alipoor SD, Jamaati H, Tabarsi P, Mortaz E. Immunopathogenesis of Pneumonia in COVID-19. Tanaffos. 2020;19(2):79–82. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13(1):5. Tian J, Xu Q, Liu S, Mao L, Wang M, Hou X. Comparison of clinical characteristics between coronavirus disease 2019 pneumonia and community-acquired pneumonia. Curr Med Res Opin. 2020;36(11):1747–52. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773–81. Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on Cardiovascular Disease. Viruses. 2023;15:508. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African guideline for the management of community- acquired pneumonia in adults. J Thorac Dis. 2017;9:1469–502. Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(12):1137–46. Jiang J, Wan R, Pan P, Hu C, Zhou R, Yin Y et al. Comparison of clinical, laboratory and radiological characteristics between covid-19 and adenovirus pneumonia: A retrospective study. Infect Drug Resist 2020;13. Zheng Y, Huang Z, Yin G, Zhang X, Ye W, Hu Z et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. Available from: https://doi.org/10.1101/2020.02.19.20024885 Li Y, Li H, Han J, Yang L. The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China. BMC Infect Dis. 2020;20(1):935. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis. 2020;71(15):756–61. Lin YH, Luo W, Wu DH, Lu F, Hu SX, Yao XY, et al. Comparison of clinical, laboratory, and radiological characteristics between SARS-CoV-2 infection and community-acquired pneumonia caused by influenza virus: A cross-sectional retrospective study. Medicine (United States). 2020;99(44):e23064. Clinical-Management-of-COVID-19-disease_Version-4(18 May. 2020. National Institute for Communicable Diseases. Accessed 24 April 2025. https://www.nicd.ac.za/wp-content/uploads/2025/05/clinical-management-of-suspected-and-confirmed-COVID-19-version-4.pdf Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–82. Health Organization W. Guideline Clinical management of COVID-19: living guideline. 2023.Accessed:24 April 2025. https://iris.who.int/bitstream/handle/10665/365580/WHO-2019-nCoV-clinical-2023.1-eng.pdf33 Zhu Q, Wu Y, Mai J, Guo G, Meng J, Fang X et al. Comprehensive Metabolic Profiling of Inflammation Indicated Key Roles of Glycerophospholipid and Arginine Metabolism in Coronary Artery Disease. Front Immunol 2022;13. Corica B, Tartaglia F, D’Amico T, Romiti GF, Cangemi R. Sex and gender differences in community-acquired pneumonia. Intern Emerg Med. 2022;17(6):1575–88. Zifodya JS, Duncan MS, So-Armah KA, Attia EF, Akgün KM, Rodriguez-Barradas MC, et al. Community-acquired pneumonia and risk of cardiovascular events in people living with HIV. J Am Heart Assoc. 2020;9(23):e017645. Di Mitri C, Arcoleo G, Mazzuca E, Camarda G, Farinella EM, Soresi M, et al. COVID-19 and non–COVID-19 pneumonia: a comparison. Ann Med. 2021;53(1):2321–31. D’ascanio M, Innammorato M, Pasquariello L, Pizzirusso D, Guerrieri G, Castelli S, et al. Age is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes. BMC Geriatr. 2021;21(1):63. Goldstein JR, Lee RD. Demographic perspectives on the mortality of COVID-19 and other epidemics. Proc Natl Acad Sci U S A 2020;117(36). Correction for Goldstein and Lee. Demographic perspectives on the mortality of COVID-19 and other epidemics. Proc Natl Acad Sci. 2020;117(14):22035–41. Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan CB, Neelima S et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science (1979). 2020;370(6517):691–697. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–11. Ahmad Malik J, Ahmed S, Shinde M, Almermesh MHS, Alghamdi S, Hussain A, et al. The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It. Saudi J Biol Sci. 2022;29:3586–99. Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29:334–43. Khedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Zein M, Hassany SM et al. Impact of comorbidities on COVID-19 outcome. MedRxiv 2020.11.28.20240267. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020;2(8):e554–67. Vidal A, Santos L. Comorbidities impact on the prognosis of severe acute community-acquired pneumonia. Porto Biomed J. 2017;2(6):265–72. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV. 2021;8(9):e554–67. Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022;9:e486–95. Brown J, Lipman M. Community-acquired pneumonia in HIV-infected individuals. Curr Infect Dis Rep. 2014;16(3):397. Zhao H, Yan X, Guo Z, Li K, Wang Z, Wang J, et al. Comparison of outcomes and characteristics of patients admitted to the ICU with COVID-19 and other community-acquired pneumonia based on propensity score matching. BMC Infect Dis. 2024;24(1):419. Chen X, Yang Y, Huang M, Liu L, Zhang X, Xu J, et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center. J Med Virol. 2020;92(9):1572–79. Mondal S, Das TK, Bhattacharya S, Banerjee S, Hazra D. Blood Gas Analysis among COVID-19 Patients: A Single Centre Retrospective Observational Study. J Clin Diagn Res. 2021;15(8):LC01–04. Sanghani H, Bansal S, Parmar V, Shah R. Study of Arterial Blood Gas Analysis in Moderate-to-Severe COVID-19 Patients. Cureus. 2022;14(7):26715. Wu C, Wang G, Zhang Q, Yu B, Lv J, Zhang S, et al. Association Between Respiratory Alkalosis and the Prognosis of COVID-19 Patients. Front Med (Lausanne). 2021;8:564635. Zhang WZ. Age-associated increase in creatine kinase-MB-specific activity in human serum confounds its use as an injury marker. Heart Lung Circ. 2005;14(2):104–6. Bezuidenhout MC, Wiese OJ, Moodley D, Maasdorp E, Davids MR, Koegelenberg CFN, et al. Correlating arterial blood gas, acid–base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. Ann Clin Biochem. 2021;58(2):95–101. Zhang L, Li Y, Zhou J, Li J, Tong C, Cai J, et al. Comparison of the community-acquired pneumonia and COVID-19 at the early stage: Findings from two cohort studies. Ann Palliat Med. 2021;10:9572–82. Paliogiannis P, Zinellu A, Scano V, Mulas G, de Riu G, Pascale RM, et al. Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: A preliminary repor t . J Infect Dev Ctries. 2020;14:685–90. Pan Y, Ye G, Zeng X, Liu G, Zeng X, Jiang X, et al. Can routine laboratory tests discriminate SARS-CoV‐2‐infected pneumonia from other causes of community‐acquired pneumonia? Clin Transl Med. 2020;10:161–8. Iepsen UW, Plovsing RR, Tjelle K, Foss NB, Meyhoff CS, Ryrsø CK et al. The role of lactate in sepsis and COVID-19: Perspective from contracting skeletal muscle metabolism. Exp Physiol 2022;107(7). Nardi G, Sanson G, Tassinari L, Guiotto G, Potalivo A, Montomoli J et al. Lactate Arterial-Central Venous Gradient among COVID-19 Patients in ICU: A Potential Tool in the Clinical Practice. Crit Care Res Pract. 2020; 2020:4742904. Carpenè G, Onorato D, Nocini R, Fortunato G, Rizk JG, Henry BM, et al. Blood lactate concentration in COVID-19: A systematic literature review. Clin Chem Lab Med. 2022;60:332–7. Faour WH, Choaib A, Issa E, Choueiry F, El, Shbaklo K, Alhajj M, et al. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. J Inflamm Res. 2022;71:39–56. Main C. Acute kidney injury: a COVID-19 update. J Kidney Care. 2021;6(1). Shafi ST. Covid-19 and Acute Kidney Injury: Recent Updates. Pak J Kidney Dis 2021;4(2). Chegini R, Mojtahedi Z, Lakkakula BV, Pezeshgi A, Niazi S, Nasri H. COVID-19 and the kidney; mechanisms of tubular injury by SARS-CoV-2. J Ren Inj Prev. 2021;10(1):e08. Hirsch JS, Ikizler TA, Sharma S, Mohammed A. Acute Kidney Injury and Advanced Kidney Disease in the COVID-19 Pandemic: Proceedings From a National Kidney Foundation Symposium. Kidney Med . 2021;3(3):426 – 32. NICE guideline. COVID-19 rapid guideline: acute kidney injury in hospital. Nice 2020.Accessed 24 April 2025: https://www.COVID-19 rapid guideline: acute kidney injury in hospital/Guideline/NICE. Vargas JG, Avila N, Hurtado D, Cárdenas-Roldán J, Peña D, Ortiz G. Acute kidney injury in COVID-19: update and literature review. Acta Colombiana de Cuidado Intensivo. 2022;22(1):24–34. Khokhar M, Purohit P, Roy D, Tomo S, Gadwal A, Modi A, et al. Acute kidney injury in COVID 19–an update on pathophysiology and management modalities. Arch Physiol Biochem. 2023;129(3):636–9. Ng JH, Bijol V, Sparks MA, Sise ME, Izzedine H, Jhaveri KD. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis. 2020;27(5):365–76. Batlle D, Soler MJ, Sparks MA, Hiremath S, South A, Welling P, et al. Acute kidney injury in COVID-19: Emerging evidence of a distinct pathophysiology. J Amer Soc Nephrol. 2020;31:1380–3. Umbro I, Gentile G, Tinti F, Muiesan P, Mitterhofer AP. Recent advances in pathophysiology and biomarkers of sepsis-induced acute kidney injury. J Infect. 2016;72(2):131–42. Izzedine H, Jhaveri KD. Acute kidney injury in patients with COVID-19: an update on the pathophysiology. Nephrol Dial Transpl. 2021;36(2):224–6. Wang M, Xiong H, Chen H, Li Q, Ruan XZ. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis. 2021;7(2):100–10. Xu Z, Tang Y, Huang Q, Fu S, Li X, Lin B, et al. Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. BMC Nephrol. 2021;22(1):52. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829–38. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Amer Soc Nephrol. 2020;316:1157–65. Li Z, Wu M, Guo J, Yao J, Liao X, Song S et al. Caution on kidney dysfunctions of 2019-nCoV patients. MedRxiv. 2020. Lippi G, Sanchis-Gomar F, Henry BM, Lavie CJ. Cardiac biomarkers in COVID-19: a narrative review. eJIFCC. 2021;32923:337–46. Mueller C, Giannitsis E, Jaffe AS, Huber K, Mair J, Cullen L, et al. Cardiovascular biomarkers in patients with COVID-19. Eur Heart J Acute Cardiovasc Care. 2021;10(3):310–9. Shi X, Chen M, Zhang Y. The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. Mol Biol Rep. 2021;48(2):310–9. Li C, Chen H. Unlike common pneumonia, COVID-19 is a risk factor for multiple cardiovascular diseases A two-sample Mendelian randomization study. Medicine (United States). 2024;103:e41015. Efros O, Soffer S, Leibowitz A, Fardman A, Klempfner R, Meisel E, et al. Risk factors and mortality in patients with pneumonia and elevated troponin levels. Sci Rep. 2020;10(1):21619. Borato DCK, Vellosa JCR. Association between soluble biomarkers-microbial translocation, inflammation and cardiovascular risk in HIV-infected individuals: A systematic review. Braz J Pharm Sci. 2020;56:18567. Robbertse PPS, Doubell AF, Esterhuizen TM, Herbst PG. Antiretroviral therapy and HIV-associated cardiovascular disease: a prospective cardiac biomarker and CMR tissue characterization study. ESC Heart Fail. 2023;11(2):748–58. Bushaku M, Nyamwange C, Kwena A, Twagirumukiza M, Nepo Utumatwishima J, Mugeni R, et al. Detection of Undiagnosed Elevated Cardiovascular Risk Biomarkers among HIV-Positive Patients on Antiretroviral Therapy (ART) in Kigali-City, Rwanda. J AIDS HIV Treat. 2023;5(1):13–21. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251–59. Donnino MW, Moskowitz A, Thompson GS, Heydrick SJ, Pawar RD, Berg KM, et al. Comparison between Patients Hospitalized with Influenza and COVID-19 at a Tertiary Care Center. J Gen Intern Med. 2021;36(6):1689–95. González-Jiménez P, Méndez R, Latorre A, Mengot N, Piqueras M, Reyes S, et al. Endothelial Damage, Neutrophil Extracellular Traps and Platelet Activation in COVID-19 vs. Community-Acquired Pneumonia: A Case–Control Study. Int J Mol Sci. 2023;24(17):13194. Additional Declarations No competing interests reported. Supplementary Files Supplentarymaterials2025.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7376744","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":518606642,"identity":"39867c3d-6b39-4a2b-875c-b5cc156f7769","order_by":0,"name":"Murimisi Mukansi","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABEUlEQVRIie3PsUrEMBjA8e8I1OU7solHT+4VcgQKLt6rtBTqUuHA5UCIDUJc9AnuJQQXx2jALn2AgoPXxU1QXCooGCsqeKHg5pD/9BH45UsAfL5/GNMAGhigncnHAVIYFL1kZ42MioHsNTP9M5Ovvf1ronq/ua7nYgybFWcvl2LM6/SkaWF3AtSs3GSPmZwZhDDnyVllMKoTeYyQTgu4YW6SgSW6I3qoNEa3lthXxvZ9TsI+iejI1ZsSyJeJlC0cxUA2HnsI6Ug6VARZmMgCwcQQoHtLdQ/dX4IwO+DbyuDWXSOXyMqpQpw7SZmR5/xVzGiYXowelB1Oy9VTuzicUFqeu8h3wa+r1k58Pp/P94feAVvxWzoIjI8cAAAAAElFTkSuQmCC","orcid":"","institution":"University of the Witwatersrand","correspondingAuthor":true,"prefix":"","firstName":"Murimisi","middleName":"","lastName":"Mukansi","suffix":""},{"id":518606643,"identity":"a43e51a9-fd36-44f9-87f1-95fc34e45889","order_by":1,"name":"Helen C. Steel","email":"","orcid":"","institution":"University of Pretoria","correspondingAuthor":false,"prefix":"","firstName":"Helen","middleName":"C.","lastName":"Steel","suffix":""},{"id":518606644,"identity":"0f79e0df-079c-4c41-88cb-7e72547c7199","order_by":2,"name":"Theresa M. Rossouw","email":"","orcid":"","institution":"University of Pretoria","correspondingAuthor":false,"prefix":"","firstName":"Theresa","middleName":"M.","lastName":"Rossouw","suffix":""},{"id":518606645,"identity":"a728d70f-ae22-4cc0-a3da-e44a6eb8f91c","order_by":3,"name":"Ismail Kalla","email":"","orcid":"","institution":"University of the Witwatersrand","correspondingAuthor":false,"prefix":"","firstName":"Ismail","middleName":"","lastName":"Kalla","suffix":""},{"id":518606646,"identity":"91f30693-ed90-402a-92f8-4093582a0b0e","order_by":4,"name":"Colin Menezes","email":"","orcid":"","institution":"University of the Witwatersrand","correspondingAuthor":false,"prefix":"","firstName":"Colin","middleName":"","lastName":"Menezes","suffix":""},{"id":518606647,"identity":"630b9527-1dec-45dc-80fb-e527408c5849","order_by":5,"name":"Martin Nieuwoudt","email":"","orcid":"","institution":"University of Stellenbosch","correspondingAuthor":false,"prefix":"","firstName":"Martin","middleName":"","lastName":"Nieuwoudt","suffix":""},{"id":518606648,"identity":"962cffdd-0487-4031-b461-a5993f37e952","order_by":6,"name":"Ronald Anderson","email":"","orcid":"","institution":"University of Pretoria","correspondingAuthor":false,"prefix":"","firstName":"Ronald","middleName":"","lastName":"Anderson","suffix":""},{"id":518606649,"identity":"66f3e729-4e9c-4490-abfa-53658755e696","order_by":7,"name":"Charles Feldman","email":"","orcid":"","institution":"University of the Witwatersrand","correspondingAuthor":false,"prefix":"","firstName":"Charles","middleName":"","lastName":"Feldman","suffix":""}],"badges":[],"createdAt":"2025-08-14 20:23:16","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7376744/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7376744/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":92230985,"identity":"68cb24e7-4fc0-413f-b1c5-790ffbb2b117","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":835312,"visible":true,"origin":"","legend":"","description":"","filename":"Manuscriptsubmitted14August2025.docx","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/b989ae6642d48d69d7c5cd8d.docx"},{"id":92230986,"identity":"9c393224-af1c-4f42-b25f-c9479e9500cb","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9189,"visible":true,"origin":"","legend":"","description":"","filename":"f493759056064886af076f8348b93ab1.json","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/dcdb76c6c554f6051056d4bb.json"},{"id":92230988,"identity":"8eb1815e-4585-4d7b-a525-3ef201144e23","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":445608,"visible":true,"origin":"","legend":"","description":"","filename":"Supplentarymaterials2025.docx","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/cc99d17962f6383250ded191.docx"},{"id":92230991,"identity":"9f42322b-7319-4141-bd1d-d8c65bb7bdf7","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":196405,"visible":true,"origin":"","legend":"","description":"","filename":"f493759056064886af076f8348b93ab11enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/d5ce2db124e6b6cc4e75f954.xml"},{"id":92230989,"identity":"36306c58-a503-4f01-82cc-58243ca96ee9","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"jpeg","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1240120,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/942212e714311e8f8bc421b6.jpeg"},{"id":92230990,"identity":"91bec10a-afe2-4adb-8241-04513aa3a8c9","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"png","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":39747,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/4775d2295c808e9f085e7eec.png"},{"id":92230993,"identity":"d92b5898-167e-4268-9655-252e84f79c86","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"png","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":250522,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/fdbcd043fa49b23ba175cd3c.png"},{"id":92230992,"identity":"dd13a379-5646-4ee2-895d-a9d0c632ae0f","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"xml","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":195834,"visible":true,"origin":"","legend":"","description":"","filename":"f493759056064886af076f8348b93ab11structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/5441262d45d526aab3232b7c.xml"},{"id":92231000,"identity":"6ded01cb-25a3-4f34-a2eb-79db1b9620f7","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"html","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":209198,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/3d849a640654ab5373f95c90.html"},{"id":92230984,"identity":"d9bf4c30-d8dc-45ee-9d64-c3afcb1f7482","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":387048,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eQuartile distribution of the five cardiac markers according to pneumonia category.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAbbreviations: BNP: brain natriuretic peptide; CAP: community-acquired pneumonia; CKMB: Creatine kinase-myoglobin binding; COVID-19: coronavirus disease 2019; NT-pro BNP: N-terminal pro-brain natriuretic peptide. Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4.\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/4947d291c23d76e22d09b65c.jpeg"},{"id":95938173,"identity":"36f18500-4f7d-4ca6-b9b8-c1691b7a9130","added_by":"auto","created_at":"2025-11-14 15:54:03","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1754504,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/4a726ef0-d287-4f55-af1f-19fd330a5fd5.pdf"},{"id":92230987,"identity":"b5c2bf98-e71b-4554-85d5-e03d1ff74bc5","added_by":"auto","created_at":"2025-09-26 06:24:52","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":445608,"visible":true,"origin":"","legend":"","description":"","filename":"Supplentarymaterials2025.docx","url":"https://assets-eu.researchsquare.com/files/rs-7376744/v1/9291df5455d379e5664456de.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"A comparison of clinical and cardiac biomarker profiles of patients with community-acquired pneumonia and with COVID-19 pneumonia in a high HIV prevalence adult population. Running title: Comparison of patients with CAP and COVID-19 pneumonia","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCommunity-acquired pneumonia (CAP) and COVID-19 pneumonia are multisystem diseases with the respiratory tract as the port of entry. Cardiovascular events (CVEs) have been documented to occur in patients with CAP and, more recently, in cases with COVID-19 pneumonia, and these events represent one of the major extrapulmonary manifestations, which contribute to the mortality and morbidity of patients with these infections. These CVEs develop in up to a quarter of cases, contributing considerably to both short- and long-term cardiac dysfunction.[\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] These CVEs may occur at the time of diagnosis of pneumonia, or during convalescence,[\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] and are evident either in patients with underlying cardiac disease or cardiovascular risk factors, as well as in those without known cardiovascular risk.[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e] Notably, cardiovascular diseases represent risk factors for both CAP and COVID-19, consistent with a bidirectional relationship.[\u003cspan additionalcitationids=\"CR7 CR8 CR9\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/p\u003e\u003cp\u003eThe pathophysiology of the CVEs involves both pathogen-mediated and/or host-mediated myocardial damage.[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] The host-mediated events are related to the systemic inflammatory/immune response to these infections by mechanisms that are not fully elucidated.[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] In approximately 20\u0026ndash;30% of COVID-19 cases, myocardial injury is indicated by elevated levels of N-terminal pro-B-type natriuretic peptide (N-Pro BNP) and cardiac troponin I (cTnI) isoenzymes and are indicative of major CVEs.[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/p\u003e\u003cp\u003eIt is difficult to differentiate between CAP and COVID-19 pneumonia on the basis of clinical symptoms and signs alone, as both have similar features. Furthermore, SARS-CoV-2 infection continues to present major clinical, diagnostic, and therapeutic challenges. Some 20% of patients with SARS-CoV-2 infection may develop severe complications, including COVID-19 pneumonia.[\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e] Notably the clinical and radiological features of patients with COVID-19 pneumonia are very similar to those of CAP, irrespective of bacterial or viral aetiology, which also frequently occurred concomitantly during the pandemic.[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e] Clearly, there is a need to differentiate between the two types of infection because they need different forms of management and therapy.[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e] Furthermore, in addition to occurring in patients with CAP, cardiovascular complications were noted to occur in patients with COVID-19 from very early on in the pandemic.[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e] These findings also suggest that the early detection, treatment and prevention of cardiovascular events will likely contribute to an improved outcome in both CAP and COVID-19 pneumonia.[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e] While the treatment of CAP is clearly outlined in most guidelines, that of COVID-19 pneumonia is still under development.[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e] Several studies have been undertaken to compare clinical, laboratory and CVEs internationally; however, there are no data from sub-Saharan Africa, among patients with a high prevalence of human immunodeficiency virus (HIV)-infection.[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan additionalcitationids=\"CR25 CR26 CR27\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]\u003c/p\u003e\u003cp\u003eGiven the propensity of patients with CAP and COVID-19 pneumonia to develop CVEs, it is somewhat surprising that few studies have been undertaken to compare the clinical and biomarker profiles of patients with these two infections and to identify differences that may exist with regard to occurrence of these events, particularly in a low-middle income country with a considerable HIV prevalence. Accordingly, the purpose of the current study was to investigate and compare demographic, clinical and routine laboratory characteristics, as well as systemic inflammatory and cardiovascular biomarker profiles in patients with CAP or COVID-19 pneumonia.\u003c/p\u003e"},{"header":"Patients and methods","content":"\u003cp\u003e\u003cem\u003eStudy population\u003c/em\u003e\u003c/p\u003e\u003cp\u003eThis was a prospective study conducted at two centres, namely the Helen Joseph Hospital (University of the Witwatersrand, Johannesburg, RSA), which enrolled CAP patients in the pre-COVID-19 era, and the Steve Biko Academic Hospital (University of Pretoria, Pretoria, RSA), which recruited patients with COVID-19 pneumonia. The study enrolled CAP cases between August 2019 and March 2020 and COVID-19 cases between March and June 2021. Cases enrolled (n\u0026thinsp;=\u0026thinsp;133) were consecutive adult patients\u0026thinsp;\u0026ge;\u0026thinsp;18 years old, hospitalized with either CAP (n\u0026thinsp;=\u0026thinsp;59) or COVID-19 pneumonia (n\u0026thinsp;=\u0026thinsp;74). A control group (n\u0026thinsp;=\u0026thinsp;15) comprising healthy, HIV-uninfected individuals was included in the study.\u003c/p\u003e\u003cp\u003e The study components were approved by the appropriate Human Research Ethics Committees (University of the Witwatersrand: reference M180382; and University of Pretoria: reference 247/2020). Written informed consent was obtained from all participants before the commencement of the study. The diagnosis of pneumonia was based on clinical signs and symptoms (cough, sputum expectoration, pleuritic chest pain, dyspnoea, and/or fever) and a radiologically-confirmed pulmonary infiltrate. Immunosuppressed individuals were included. The exclusion criteria were: 1) nosocomial infection, occurring more than 48 hours after admission and/or hospitalization in the preceding 90 days; 2) children below 18 years of age; and 3) aspiration pneumonitis.\u003c/p\u003e\u003cp\u003eSARS-CoV-2 infection was confirmed using a polymerase chain reaction (PCR) test on nasopharyngeal swabs, in accordance with the recommendations of the National Institute for Communicable Diseases, Johannesburg, RSA.[\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e] The CAP patients presented before the pandemic, prior to the availability of tests for SARS-CoV-2, so no tests to rule out COVID-19 were done or indicated in that group. The severity of CAP was based on the CURB-65 score (a 5-point severity of illness score).[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] while that of COVID-19 pneumonia was based on the WHO severity score. These scores subdivided COVID-19 into mild, moderate, and severe or critical.[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] A detailed medical history and examination were obtained on admission for all enrolled patients, including current symptoms and duration, as well as previous illnesses and data on relevant chronic medication.\u003c/p\u003e\u003cp\u003e\u003cem\u003eLaboratory testing\u003c/em\u003e\u003c/p\u003e\u003cp\u003eRoutine laboratory testing was done as part of standard of care, including full blood count, urea and electrolytes, C-reactive protein (CRP) and procalcitonin (PCT). Samples were processed at the National Health Laboratory Services, Johannesburg, RSA. In addition, levels of study-specific biomarkers\u003csup\u003e,\u003c/sup\u003e B-natriuretic peptide (BNP), creatine kinase-MB (CK-MB), endocan-1, NT-pro BNP and troponin I were measured using a Milliplex\u0026reg; MAP Human Cardiovascular Disease panel (Merck, DE). The biomarkers were analysed using a Bio-Plex suspension array platform (Bio-Rad, Hercules, CA, USA). All methods were followed as outlined by the manufacturers. These assays were undertaken at the Department of Immunology, University of Pretoria. For measurement of cardiac and inflammatory biomarkers, plasma was processed and stored at -80 \u0026ordm;C prior to analysis.\u003c/p\u003e\u003cp\u003e\u003cem\u003eStatistical analyses\u003c/em\u003e\u003c/p\u003e\u003cp\u003eStatistical analyses were performed using Stata 17 (Stata Statistical Software: Release 17. StataCorp LLC, College Station, TX). Data were expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) for parametric parameters and median\u0026thinsp;\u0026plusmn;\u0026thinsp;interquartile range (IQR) for the parameters with a non-Gaussian distribution. Categorical/binary values are presented as counts and percentages with comparisons performed by means of the Pearson\u0026rsquo;s chi-square or Fisher\u0026rsquo;s exact tests. Comparisons of continuous variables were made using the parametric tests (paired and unpaired Student\u0026rsquo;s t-test) and non-parametric tests (Kruskal-Wallis test with the post-hoc Dunn test for unpaired samples and the Wilcoxon sign-rank test for paired samples), with p-values\u0026thinsp;\u0026le;\u0026thinsp;0.05 considered statistically significant.\u003c/p\u003e\u003cp\u003eGiven the relatively small sample size and the large number of predictor variables, formal regression analysis was not undertaken. Limited regression analysis for the different sets of variables was, however, conducted to support the results of the univariate analysis. All predictor variables that were significant in the univariate analysis were transformed, if necessary, and entered in the multivariable logistic regression analysis in a stepwise backwards manner. Variables with multicollinearity were removed.\u003c/p\u003e\u003cp\u003eAn inflammation score was calculated based on the work of Zhu \u003cem\u003eet al\u003c/em\u003e.[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e] Briefly,\u003c/p\u003e\u003cp\u003ethe score is composed of four serum and cellular circulating inflammatory markers, namely CRP, WBC, platelet count, and granulocyte-to-lymphocyte ratio. Each value is calculated based on 10 tiles of each biomarker level. The highest (7\u0026ndash;10) and lowest (1\u0026ndash;4) deciles are scored as positive and negative from 1 to 4, respectively, and deciles 5\u0026ndash;6 are scored as zero. The total score is the sum of the four biomarkers and ranges from \u0026minus;\u0026thinsp;16 to 16.\u003c/p\u003e\u003cp\u003eSpearman\u0026rsquo;s correlation with Bonferroni correction for multiple comparisons was performed for clinical and laboratory variables of interest.\u003c/p\u003e\u003cp\u003eGiven HIV- and sex-related differences in CAP and COVID-19 mortality,[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] additional comparisons were made between patients with and without HIV infection and those patients who identified as male and female, respectively. These analyses were performed in the two groups combined\u003csup\u003e,\u003c/sup\u003e as well as in the CAP and COVID-19 groups separately.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eTable 1 shows the demographic information, underlying co-morbid conditions, and clinical findings of the patients with CAP and those with COVID-19 pneumonia at initial presentation. Patients with CAP were significantly younger than patients with COVID-19. Among the co-morbidities, the frequency of HIV-positivity was significantly higher in patients with CAP compared to those with COVID-19 pneumonia (45.8% versus [vs] 32.4%; p=0.032). In contrast, the frequencies of neoplastic diseases, chronic heart disease, diabetes mellitus, chronic obstructive airway disease\u003cstrong\u003e,\u0026nbsp;\u003c/strong\u003ehypertension, and coronary artery disease were significantly higher in the COVID-19 group. Use of pharmacological agents, such as beta-blockers and angiotensin-converting enzyme inhibitors (ACEI), was significantly higher in patients with COVID-19 pneumonia (4.1% vs 1.7% and 4.1% vs 3.4%, respectively; p\u0026lt;0.001 for both agents), reflecting the higher prevalence of co-morbid disease in this group. \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePatients with COVID-19 pneumonia had a longer duration of respiratory symptoms at presentation and were more likely to have dyspnoea than patients with CAP. In contrast, cough and fever were significantly more common in the CAP group. The systolic and diastolic blood pressure, as well as the respiratory rate were lower, while the heart rate was higher in\u0026nbsp;patients admitted with CAP.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1: Demographics, co-morbidities and clinical characteristics of patients with CAP versus COVID-19 pneumonia.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAP\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=59)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCOVID-19 pneumonia\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=74)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e-\u003cstrong\u003evalue\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eDemographic information\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Age (years) (mean \u0026plusmn; SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e44.3 (\u0026plusmn; 13.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e53.1 (\u0026plusmn; 13.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Gender\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e27 males: 32 females\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e36 males: 38 females\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.811\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCo-morbidities\u0026nbsp;\u003c/strong\u003e[n (%)]\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; HIV\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e27 (45.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e24 (32.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.032\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Neoplastic disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3 (4.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.021\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Chronic kidney disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1 (1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4 (5.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.065\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Chronic heart disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1 (1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8 (10.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Diabetes mellitus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5 (8.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e20 (27.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; COPD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1 (1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5 (6.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.005\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Hypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4 (6.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e27 (36.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSymptoms\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Number of days symptomatic\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5 (3 \u0026ndash; 6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e7 (5 \u0026ndash; 9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Cough\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e56/56 (100%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e43/54 (79.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Fever\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e27/56 (48.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e21/54 (38.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dyspnoea\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e29/56 (51.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e45/54 (83.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Sputum expectoration\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e36/56 (64.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eNot recorded\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eClinical Features\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Systolic BP (mmHg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e112.5 (98.5 \u0026ndash; 131)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e126 (117 \u0026ndash; 139)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.003\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Diastolic BP (mmHg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e67.5 (55.5 \u0026ndash; 82.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e79 (69 \u0026ndash; 86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Respiratory rate (breaths/min)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e22 (19 \u0026ndash; 24)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e26 (22 \u0026ndash; 30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Heart rate (beats/min)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e112 (103 \u0026ndash; 127)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e100 (90 \u0026ndash; 109.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e*\u0026nbsp;Maximum creatinine clearance was taken as 60 mL/min.\u003c/p\u003e\n\u003cp\u003eResults are reported as median (interquartile range) unless indicated otherwise.\u003c/p\u003e\n\u003cp\u003eValues in bold denote significance.\u003c/p\u003e\n\u003cp\u003eAbbreviations: BP: Blood pressure; CAP: community-acquired pneumonia; COPD: Chronic obstructive pulmonary disease; COVID-19: COVID-19 pneumonia; HIV: Human immunodeficiency virus.\u003c/p\u003e\n\u003cp\u003eThe CAP patients generally had mild or moderate disease. Only three (5%) patients had severe disease according to the CURB-65 score (CURB-65 \u0026gt;3). Of the COVID-19 patients, 13/61 (21.3%) with disease severity recorded, had severe disease. This was significantly more than the CAP patients presenting with the equivalent CURB-65 score (21.3% vs 5%; p=0.014).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn multivariable regression analysis, the clinical symptoms of less dyspnoea and fewer symptomatic days, together with a higher heart rate, distinguished patients with CAP from those with COVID-19 pneumonia (Supplementary Table 1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2: Routine laboratory parameters of patients with CAP versus COVID-19 pneumonia.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eLaboratory parameters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAP \u0026nbsp; \u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=59)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCOVID-19 pneumonia\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;(n=74)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eArterial blood gas\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; pH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7.43 (7.38 \u0026ndash; 7.47)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 7.47 (7.42 \u0026ndash; 7.51)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.004\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; SpO\u003csub\u003e2\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e78.25 (66.05 \u0026ndash; 94.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e93 (90 \u0026ndash; 96)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; HCO\u003csub\u003e3-\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e21.15 (20 \u0026ndash; 23.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e20 (18 \u0026ndash; 22.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.027\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Lactate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2 (1.3 \u0026ndash; 2.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1.35 (0.9 \u0026ndash; 1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.004\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;PaO\u003csub\u003e2\u003c/sub\u003e/FiO\u003csub\u003e2\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e199 (149 \u0026ndash; 280)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e183.2 (104.4 \u0026ndash; 391.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.236\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eHIV\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; CD4\u003csup\u003e+\u0026nbsp;\u003c/sup\u003eT-cell count (cells/mm\u003csup\u003e3\u003c/sup\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e197 (156 \u0026ndash; 298.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e212 (117 \u0026ndash; 296)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.381\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; HIV viral load (copies/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1,850 (69.5 \u0026ndash; 81,500)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e20 (20 \u0026ndash; 12,738)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.006\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eHaematology\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;WBC\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e13.48 (9.20 \u0026ndash; 18.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8.54 (6.85 \u0026ndash; 10.86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;PMN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e11.46 (6.23 \u0026ndash; 17.02)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e7.32 (5.29 \u0026ndash; 9.55)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.040\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lymphocytes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1.44 (1.04 \u0026ndash; 1.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1.11 (0.75 \u0026ndash; 1.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.072\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;PMN/lymphocyte ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6.78 (4.07 \u0026ndash; 11.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6.84 (4.27 \u0026ndash; 10.74)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.490\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Platelets\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;262.5 (192.5 \u0026ndash; 313.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e261.5 (184 \u0026ndash; 352)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.362\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Platelet/lymphocyte ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;151 (80 \u0026ndash; 238)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e277 (162 \u0026ndash; 382)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.010\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eInflammatory biomarkers\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; CRP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e235.5 (109 \u0026ndash; 310)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e113 (69.5 \u0026ndash; 215.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.004\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; PCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.81 (0.68 \u0026ndash; 62.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.09 (0.04 \u0026ndash; 0.40)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.003\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eUrea and electrolytes\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Na\u003csup\u003e+\u003c/sup\u003e (mean \u0026plusmn; SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e134 \u0026plusmn;5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e136 \u0026plusmn;3.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.027\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; K\u003csup\u003e+\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4.0 (3.5 \u0026ndash; 4.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4.4 (4.0 \u0026ndash; 5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; BUN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5.6 (3.8 \u0026ndash; 9.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5.3 (3.7 \u0026ndash; 8.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.263\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Creatinine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e86 (64 \u0026ndash; 124)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e71 (59 \u0026ndash; 95)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.032\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Creatinine clearance* (mL/min)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e60 (42 \u0026ndash; 60)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e60 (60 \u0026ndash; 60)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; HbA1c\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6.1 (5.7 \u0026ndash; 7.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e6.3 (5.8 \u0026ndash; 7.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.333\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eLiver function\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;AST\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e46 (27 \u0026ndash; 104)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e39 (24 \u0026ndash; 61)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.126\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;ALT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e45 (27 \u0026ndash; 72)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e28 (18 \u0026ndash; 47)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.011\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;ALP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e83 (64 \u0026ndash; 119)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e81 (68 \u0026ndash; 116)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.381\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;GGT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e53.5 (28 \u0026ndash; 99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e71 (42 \u0026ndash; 133)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.069\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e* Maximum creatinine clearance was taken as 60 mL/min.\u003c/p\u003e\n\u003cp\u003eResults are reported as median (interquartile range) unless indicated otherwise.\u003c/p\u003e\n\u003cp\u003eValues in bold denote significance.\u003c/p\u003e\n\u003cp\u003eAbbreviations: ALP: Alkaline phosphatase; ALT: Alanine transaminase; AST: Aspartate transaminase; BUN: Blood urea nitrogen; CRP: C-reactive protein; CD4: Cluster of differentiation 4; FiO\u003csub\u003e2\u003c/sub\u003e: fraction of inspired oxygen; GGT: gamma-glutaryl transaminase; HCO\u003csub\u003e3\u003c/sub\u003e: bicarbonate; HIV: Human immunodeficiency virus; K\u003csup\u003e+\u003c/sup\u003e: potassium; Na\u003csup\u003e+\u003c/sup\u003e: Sodium; PaO\u003csub\u003e2\u003c/sub\u003e: Partial pressure of oxygen; PCT: Procalcitonin; PMN: Polymorphonuclear cells; SpO\u003csub\u003e2\u003c/sub\u003e: peripheral oxygen saturation; WBC: white blood cells.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThere were several significant differences in the routine laboratory parameters between the two groups, with important highlighted differences being a lower peripheral oxygen saturation (SpO\u003csub\u003e2\u003c/sub\u003e), but higher creatinine, white cell count, CRP and PCT in the CAP group, compared with the COVID-19 group (Table 2). As is evident from Table 2, patients with CAP and HIV (with an HIV viral load [VL] available), had significantly higher VLs than the patients with COVID-19 pneumonia and HIV. Significantly more patients admitted with CAP had a detectable VL i.e. \u0026gt; 50 copies/mL (CAP 13/16 vs COVID-19 10/24; p=0.014) and numerically more had levels above 1,000 copies/mL (CAP 10/16 vs COVID-19 7/24; p=0.053) and 100,000 copies/mL (CAP 4/16 vs COVID 1/24; p=0.073), although the latter two differences did not reach statistical significance. The difference in VL suggests that CAP might have been the presenting clinical presentation in these patients. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn the regression model, PCT predicted the data perfectly. A log-transformed value of PCT of\u0026nbsp;\u0026pound;\u0026nbsp;2.087 predicted the outcome (CAP vs COVID-19) with 100% accuracy, precluding its inclusion in the multivariable model. Among the remaining variables, a low SpO\u003csub\u003e2\u003c/sub\u003e and creatinine clearance, together with a high CRP differentiated CAP the best from COVID-19 pneumonia (Supplementary Table 2). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe inflammatory score was calculated for both groups. The CAP group (n=10) had a mean score of 0 (SD \u0026plusmn;6.36) with a lowest score of -7 and a highest score of 10. The COVID-19 group (n=44) had a mean score of -0.39 (SD \u0026plusmn;6.16) with a lowest score of -16 and a highest score of 11. The inflammatory score correlated well with the WHO COVID-19 severity score: Mild disease had a mean of -6.25 (SD \u0026plusmn;8.66); moderate disease had a mean of -0.56 (SD \u0026plusmn;5.58) and severe disease had a mean of 2.5 (SD 5.84). Due to the small number of CAP patients with all variables recorded, further analysis was not conducted.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3. Comparison of cardiovascular biomarkers in participants with CAP, COVID-19, and healthy control individuals.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"633\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBiomarkers\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAP\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e(n=59)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCOVID-19\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e(n=74)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eControls\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e(n=15)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAP vs COVID\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAP vs Controls\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCOVID vs Controls\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBNP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e78.26\u003c/p\u003e\n \u003cp\u003e(54.74-109.10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e63.89\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(63.89-116.21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e75.41\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(57.87-91.60)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.377\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.4702\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.388\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eNT-pro BNP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e219.47\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(157.95-496.29)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e232.08\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(155.39-401.96)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e128.56\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(34.29-186.89)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.466\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCK-MB\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3,023.57\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(1741.37-7037.52)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4,316.19\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(2805.97-8115.60)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2,239.70\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(712.44-4\u0026nbsp;215.44)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.028\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.038\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eTroponin-I\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e109.94\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(68.59-335.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e377.38 \u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(190.35-879.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e129.77\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(88.75-232.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.310\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eEndocan-1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1,735.86\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(988.60-2522.52)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2,354.55\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(963.00-3716.34)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e368.45\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(19.45-812.69)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.123\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eResults are reported as pg/mL\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eValues in bold denote significance.\u003c/p\u003e\n\u003cp\u003eAbbreviations: BNP: brain natriuretic peptide; CKMB: Creatine kinase-myoglobin binding; NT-pro BNP: N-terminal pro-brain natriuretic peptide.\u003c/p\u003e\n\u003cp\u003eTable 3 shows a univariate comparison of the cardiac biomarkers in patients with CAP, COVID-19 pneumonia, and healthy control individuals. NT-pro-BNP, CK-MB, and endocan-1 were significantly higher in patients with CAP compared to the control group. Results were similar for those with COVID-19 pneumonia, except that troponin I, in addition, was also higher than the control group. Both CK-MB and troponin I were significantly higher in patients with COVID-19 pneumonia than in those with CAP.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAbbreviations: BNP: brain natriuretic peptide; CAP: community-acquired pneumonia; CKMB: Creatine kinase-myoglobin binding; COVID-19: coronavirus disease 2019; NT-pro BNP: N-terminal pro-brain natriuretic peptide. Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDifferences were also evident between the CAP and COVID-19 groups when the cardiac markers were divided into quartiles (Figure 1). Patients with CAP were significantly more likely to be in the first and third quartile of BNP; in the first quartile of troponin I; and numerically, but non-significantly, in the first quartile of CK-MB. In contrast, patients with COVID-19 pneumonia were more likely to be in the fourth quartile of all the cardiac biomarkers, significantly so in the case of BNP and troponin I. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eRegression analysis showed that troponin I was the best discriminator between CAP and COVID-19 pneumonia (Supplementary Table 3).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4 Gender analysis for CAP and COVID-19 pneumonia cases combined.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBiomarkers\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eMale\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e(n=63)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eFemale\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e(n=69)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eP-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBNP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e63.89 (54.74 \u0026ndash; 91.76)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e81.00 (54.74 \u0026ndash; 118.62)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.055\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eNT-pro BNP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e203.85 (139.11 \u0026ndash; 424.22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e253.03 (168.17 \u0026ndash; 424.90)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.173\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCK-MB\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3,414.84 (1\u0026nbsp;973.84 \u0026ndash; 7\u0026nbsp;148.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3,791.43 (2\u0026nbsp;322.82 \u0026ndash; 9\u0026nbsp;295.14)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.171\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eTroponin I\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e190.35 (68.59 \u0026ndash; 514.39)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e321.68 (119.94 \u0026ndash; 879.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.024\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eEndocan-1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1,588.82 (731.94 \u0026ndash; 3\u0026nbsp;136.50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2,054.73 (1\u0026nbsp;295.80 \u0026ndash; 3\u0026nbsp;460.84)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.034\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eResults are reported as pg/mL.\u003c/p\u003e\n\u003cp\u003eValues in bold denote significance.\u003c/p\u003e\n\u003cp\u003eAbbreviations: BNP: brain natriuretic peptide; CK-MB: Creatine kinase-myoglobin binding; NT-pro BNP: N-terminal pro-brain natriuretic peptide.\u003c/p\u003e\n\u003cp\u003eSub-analysis of sex within the CAP and COVID-19 groups combined revealed significantly higher levels of troponin I and endocan-1 in women (Table 4). In the individual groups, no significant differences were seen between the two sexeswith CAP, while in the COVID-19 group, troponin I was significantly higher in women (p=0.005) (Supplementary Table 4).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5. Correlations matrix\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" alt=\"image\"\u003e\u003c/p\u003e\n\u003cp\u003eAbbreviations: ALT: alanine transaminase; BNP: brain-type natriuretic peptide; CK-MB: creatinine kinase-myoglobin binding; CRP: C-reactive protein; HCO3: bicarbonate; K: potassium; Na: sodium; NT-pro BNP: N-terminal prohormone of brain natriuretic peptide; PCT: procalcitonin; PMN: polymorphonuclear leukocyte count; PLR: platelet lymphocyte ratio; SpO2: peripheral oxygen saturation; WBC: white blood cell count.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAnnotations: Red indicates negative, and blue indicates positive correlations, with the shades indicating the strength of the correlation. The numbers in bold indicate significance.\u003c/p\u003e\n\u003cp\u003eThere were no significant differences between people with and without HIV when comparing the total pneumonia population. Sub-analysis of the two pneumonia groups separately demonstrated no differences in patients with CAP with and without HIV infection (Supplementary Table 5). In contrast, patients with SARS-CoV-2-HIV coinfection had significantly higher levels of BNP (p=0.009), troponin I (p=0.016), and endocan-1 (p=0.019), and non-significantly higher levels of NT-proBNP (p=0.077) than patients with COVID-19 and without HIV (Supplementary Table 5). No significant associations were detected between the cardiac markers of people with HIV infection and either CD4+ T-cell count or VL.\u003c/p\u003e\n\u003cp\u003eWith regard to the various correlations, there were significant positive correlations between some of the cardiac biomarkers, in particular BNP and NT-proBNP with each other, and with troponin I. Of the remaining variables there were also positive correlations between the following variables: Age with heart rate; SpO\u003csub\u003e2\u003c/sub\u003e with both heart rate and serum sodium; pH with HCO\u003csub\u003e3\u003c/sub\u003e; and white blood cell count with creatinine (range of rho values: 0.61-0.70; corresponding range of p values: 0.049-0.018). On the contrary, the following variables showed significant negative correlations, Age with SpO\u003csub\u003e2\u003c/sub\u003e and troponin I; diastolic blood pressure with lactate; heart rate with SpO\u003csub\u003e2\u003c/sub\u003e, CK-MB and troponin I; pH with serum potassium; platelet lymphocyte ratio with BNP, NT-proBNP and troponin I; CRP with troponin I; PCT with serum sodium; and ALT with CKMB (range of rho values: -0.62-0.83; corresponding range of p values: 0.041-0.003) (Table 5. Correlations matrix).\u003c/p\u003e\n\u003cp\u003eWhile systemic and cardiac biomarkers were measured in both groups, no patients were documented to have had any clinically apparent CVEs. In addition, only one patient in the CAP group died and none in the COVID-19 pneumonia group. Therefore, the association of the biomarkers with the occurrence of CVE or mortality could not be evaluated.\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe main findings of this study were that several features distinguishedpatients with CAP from those withCOVID-19pneumonia\u003csup\u003e,\u0026nbsp;\u003c/sup\u003eincludingdemographics, comorbidities, signs and symptoms, routine laboratory parametersas well as cardiac biomarkers. These included a younger age of the CAP cohort, more comorbidities in the COVID-19 cohort aside from HIV, which was more common in the CAP cases, a higher duration of respiratory symptoms prior to hospital presentation in the COVID-19 patients, with dyspnoea being more common, but lower peripheral oxygen saturation, higher WBC count, CRP and PCT, as well as a lower creatinine clearance in the CAP group. There were raised cardiac biomarkers in both pneumonia groups compared to the control cohort, while CK\u003csup\u003e-\u003c/sup\u003eMB and troponin\u0026nbsp;I were higher in the COVID-19 cases than in the CAP cases.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eAge\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eCAP patients were younger and were more commonly HIV-infected than the COVID-19 pneumonia cases who were older and had more general co-morbidities other than HIV. This differs from the findings in an Italian study, which indicated non-COVID-19 patients as being relatively older with significant co-morbidities.[35]Furthermore, COVID-19 has been observed to be highly prevalent, particularly severe\u003csup\u003e,\u003c/sup\u003e and potentially lethal in the elderly population.[36]These differences may be due to an association between the socioeconomic development levels of different countries, as well as the population age gap, with age also related to severity of illness and mortality.[37–40]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCo-morbidities\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe literature confirms the finding that a global increase in morbidity and mortality occurs in patients withCOVID-19 with comorbidities when compared with those without.[41–43]Hypertension, diabetes mellitus, and chronic heart\u0026nbsp;disease areamongthe most prevalent co-morbidities, similar to those indicated in Table1 of the current study.[44] The increase in the risk of SARS-CoV-2 infection is doubled in cases of multimorbidity.[44]In CAP, similarly, there is anassociated increase in the incidence of the disease and also worse outcomes of pneumonia.[45]The VL was significantly elevated in the CAP group compared to the COVID-19 group of patients (Table 2).\u0026nbsp;The difference in VL suggests that CAP might have been the presenting clinical presentation in these patients.\u0026nbsp;Previous studies have documented an increased risk of CAP in patients with poorly controlled HIV, while the relationship documented in patients with\u0026nbsp;HIV and\u0026nbsp;COVID-19 includes both severity of COVID-19 and mortality.[46–48]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSigns and symptoms. \u0026nbsp;\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe duration of symptoms in this cohort was significantly longer in COVID-19 pneumonia patients compared to the CAP patients, confirming the findings of Zhao \u003cem\u003eet al.\u003c/em\u003e[49] However, cough and fever were more frequent in the CAP group, as opposed to dyspnoea, which was more significant in the COVID-19 cohort. In the study by Zhao \u003cem\u003eet al\u003c/em\u003e.\u003cem\u003e[27]\u003c/em\u003e, the symptoms were similar between the two groups, which is also in contrast to Chen \u003cem\u003eet al.\u003c/em\u003e, who observed that fever and cough were more common in their patients with COVID-19than in those with CAP.[27,50]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eBlood gas analysis\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eOn admission, arterial blood gas analysis showed significantly different abnormalities between the COVID-19 group compared to the CAP group. The need for oxygen was more evident in the CAP group compared with the COVID-19 group. There was significant respiratory alkalosis, with compensation as evidenced by elevated pH, and lower bicarbonate, in the COVID-19 group of patients. These observations are corroborated in many studies where the blood acid-base status ranges from respiratory to metabolic acidosis or alkalosis, although with respiratory alkalosis in the majority of these.[51–53]Various pathophysiological mechanisms are involved including fever, dysregulation of the renin-angiotensin system, multi-organ inflammation, thrombogenesis, respiratory tract infections and carotid body suppression, with the predominance of each contributing to underlying acid-base shift at different stages of COVID-19.[51–55]\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLaboratory parameters\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe CAP group had significantly higher leukocyte counts, as well as levels of CRP and PCT, possibly underscoring the differences between bacterial and viral infections. The trend of the first three parameters is in keeping with observations described in the international literature, with the elevation of these inflammatory markers pointing towards a greater severity of infection.[56–58] However, in the study by Zhao \u003cem\u003eet al\u003c/em\u003e., there was no significant difference in these biomarkers between the SARS-CoV-2-seronegative and -seropositive patients with pneumonia.[27] \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFurthermore, lactate was significantly higher in patients with CAP compared to the COVID-19 group. This is corroborated by several authors.[59,60] Unlike in CAP, lactate remains near-normal amongst patients with COVID-19 despite an elevated lactate dehydrogenase. It is likely that mitochondrial function is preserved in SARS-CoV-2 infection, despite a hyperinflammatory state, unlike in non-COVID-19 CAP.[59,61]\u003c/p\u003e\n\u003cp\u003eCreatinine clearance was lower in the patients with CAP patients compared to those with COVID-19 pneumonia. Renal dysfunction is a sign of pneumonia progression in both CAP and COVID-19 patients, as indicated in several studies.[62–75] These\u0026nbsp;\u003c/p\u003e\n\u003cp\u003estudies describe high blood urea nitrogen and serum creatinine levels as markers of renal dysfunction. Furthermore, there is a glomerular filtration rate reduction, usually measured by laboratory creatinine clearance. In addition, in severe COVID-19, the elevation of serum creatinine is associated with an increased number of leukocytes, low levels of lymphocytes and platelets, as well as coagulopathy.[74,76–78]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCardiovascular biomarkers\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eCardiac biomarkers were mostly elevated in both CAP and COVID-19 cases relative to the control group (Table 3). However,\u0026nbsp;a comparison between the CAP and COVID-19 groups revealed that the levels of CK-MB and cardiac troponin I were significantly elevated in COVID-19 pneumonia as compared to CAP (Table 3). This contention was confirmed by the data shown in Figure 1. The literature corroborates this observation.[79–81]Furthermore\u003csup\u003e,\u003c/sup\u003e when analysing the data comparing HIV-positive versus \u003csup\u003e-\u003c/sup\u003enegative cases, there were no differences in the cardiac biomarker levels in the CAP group, but notable differences in the COVID-19 group, which attained statistical significance for BNP, troponin I and endocan-1, with trends toward significance in NT-pro-BNP and CK\u003csup\u003e-\u003c/sup\u003eMB. These findings are in agreement with previous studies suggesting that patients with COVID-19 have a greater propensity to develop cardiac injury compared to a non-COVID-19 pneumonia group.[82,83] and particularly, with respect to the current study, among patients living with HIV. This is compatible with the known effects of HIV infection on the risk of cardiovascular disease. These excess cardiovascular risks persist despite the advent of the modern anti-retroviral therapy era. (85–87 The mechanism of this association between HIV infectivity and elevated cardiac biomarkers in COVID-19, which to the best of our knowledge has not been documented previously, requires further elucidation.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003ePotential limitations\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAs far as we are aware, this is the first study in sub-Saharan Africa to compare the characteristics of patients with CAP and those with COVID-19 pneumonia, and to describe the systemic inflammatory and cardiac biomarker differences between the two groups, both in the presence and absence of concurrent HIV infection. The findings of the current study will add further to the few global studies, which have compared clinical and laboratory parameters between these two groups. [19,24,28,34,57,87–89] However, this study also has some potential limitations. Firstly, it was conducted in only two institutions, so the findings may not be generalizable to the rest of sub-Saharan Africa or even South Africa. Secondly, while systemic inflammatory and cardiac biomarkers were measured in both groups, there was no systematic evaluation for the presence of clinically apparent CVEs, although it appears that none of the primary doctors looking after the patients were alerted to the risk of their development or appeared to be concerned about such events. Thirdly, data were not collected on antiretroviral therapy in the CAP group, so unfortunately, we were not able to determine the possible impact of antiretroviral therapy on any of the findings, particularly the changes in cardiac biomarkers. Fourthly, there was a lack of severe infections in both groups, so a comparison of characteristics in the context of severe versus mild-to-moderate disease was not possible, and only a single mortality was recorded in the CAP group, making it impossible to determine features associated with mortality. Fifthly, there was no long-term follow-up of the patients to allow evaluation of the occurrence of longer-term CVEs and associated cardiovascular biomarker level changes in either of our study groups. Lastly, since only in-hospital patients were recruited, the results cannot be extrapolated to out-patients.\u0026nbsp;\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThere were a number of differences in demographic, routine laboratory parameters, as well as systemic inflammatory and cardiovascular biomarkers when comparing patients with CAP and patients with COVID-19 pneumonia. The systemic inflammatory response appeared to be more pronounced in patients with CAP. However, while cardiac biomarkers were raised in both patients with CAP and COVID-19 pneumonia compared to control individuals, this was more so in the latter group, and especially in those who were HIV-positive. Based on the cardiac biomarker analysis, patients with COVID-19 pneumonia who are living with HIV would appear to be at greater risk of developing CVEs, or possibly exacerbations of pre-existing cardiac conditions, than patients with CAP. \u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent\u003c/strong\u003e: Approved by the Human Research Ethics Committees of the University of the Witwatersrand (Ref: M180382) and University of Pretoria (Ref: 247/2020). Written informed consent obtained from all participants.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u0026nbsp;\u003c/strong\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeclaration of competing interests:\u0026nbsp;\u003c/strong\u003eThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper\u003cstrong\u003e.\u0026nbsp;\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions:\u0026nbsp;\u003c/strong\u003eMM, TR, RA, and CF, were responsible for the conceptualisation of the study. MM, HCS, and TMR, were involved in data curation. MM, HCS, TMR, RA and CF accessed and verified the data. TMR and NM undertook the statistical analysis. MM wrote the first draft of the manuscript. MM, HCS, TMR, MN, IK, CM, RA, and CF edited and reviewed the manuscript several times. All authors have seen and approved the final manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData statement:\u0026nbsp;\u003c/strong\u003eData will be made available upon reasonable request.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding sources: 1.\u0026nbsp;\u003c/strong\u003eDepartment of Internal Medicine, RINC funding, Faculty of Health Sciences, University of the Witwatersrand.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.\u003c/strong\u003e Discovery Foundation PhD Scholarship Award, Discovery Health (PTY)LTD\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u0026nbsp;\u003c/strong\u003eNot applicable.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eChakafana G, Mutithu D, Hoevelmann J, Ntusi N, Sliwa K. Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot. Clin Res Cardiol. 2020;109:1460\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDesai A, Aliberti S, Amati F, Stainer A, Voza A. Cardiovascular Complications in Community-Acquired Pneumonia. Microorganisms. 2022;10(11):2177.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eStotts C, Corrales-Medina VF, Rayner KJ. Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities. Circ Res. 2023;132:751\u0026ndash;74.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMadjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5:831\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCorrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCenko E, Badimon L, Bugiardini R, Claeys MJ, De Luca G, De Wit C, et al. Cardiovascular disease and COVID-19: A consensus paper from the ESC Working Group on Coronary Pathophysiology \u0026amp; Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovasc Res. 2021;117:2705\u0026ndash;29.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGriffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. Int J Infect Dis. 2013;17(12):e1125\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRamirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eReyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med. 2017;196(5):609\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFeldman C, Anderson R. Community-acquired pneumonia: Pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148(2):523\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eShao HH, Yin RX. Pathogenic mechanisms of cardiovascular damage in COVID-19. Mol Med. 2024;30.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZheng KI, Feng G, Liu WY, Targher G, Byrne CD, Zheng MH. Extrapulmonary complications of COVID-19: A multisystem disease? J Med Virol. 2021;93:323\u0026ndash;35.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAlipoor SD, Jamaati H, Tabarsi P, Mortaz E. Immunopathogenesis of Pneumonia in COVID-19. Tanaffos. 2020;19(2):79\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFeldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13(1):5.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTian J, Xu Q, Liu S, Mao L, Wang M, Hou X. Comparison of clinical characteristics between coronavirus disease 2019 pneumonia and community-acquired pneumonia. Curr Med Res Opin. 2020;36(11):1747\u0026ndash;52.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCorrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773\u0026ndash;81.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVosko I, Zirlik A, Bugger H. Impact of COVID-19 on Cardiovascular Disease. Viruses. 2023;15:508.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBoyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African guideline for the management of community- acquired pneumonia in adults. J Thorac Dis. 2017;9:1469\u0026ndash;502.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(12):1137\u0026ndash;46.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJiang J, Wan R, Pan P, Hu C, Zhou R, Yin Y et al. Comparison of clinical, laboratory and radiological characteristics between covid-19 and adenovirus pneumonia: A retrospective study. Infect Drug Resist 2020;13.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZheng Y, Huang Z, Yin G, Zhang X, Ye W, Hu Z et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1101/2020.02.19.20024885\u003c/span\u003e\u003cspan address=\"10.1101/2020.02.19.20024885\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi Y, Li H, Han J, Yang L. The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China. BMC Infect Dis. 2020;20(1):935.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis. 2020;71(15):756\u0026ndash;61.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLin YH, Luo W, Wu DH, Lu F, Hu SX, Yao XY, et al. Comparison of clinical, laboratory, and radiological characteristics between SARS-CoV-2 infection and community-acquired pneumonia caused by influenza virus: A cross-sectional retrospective study. Medicine (United States). 2020;99(44):e23064.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eClinical-Management-of-COVID-19-disease_Version-4(18 May. 2020. National Institute for Communicable Diseases. Accessed 24 April 2025. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.nicd.ac.za/wp-content/uploads/2025/05/clinical-management-of-suspected-and-confirmed-COVID-19-version-4.pdf\u003c/span\u003e\u003cspan address=\"https://www.nicd.ac.za/wp-content/uploads/2025/05/clinical-management-of-suspected-and-confirmed-COVID-19-version-4.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHealth Organization W. Guideline Clinical management of COVID-19: living guideline. 2023.Accessed:24 April 2025. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://iris.who.int/bitstream/handle/10665/365580/WHO-2019-nCoV-clinical-2023.1-eng.pdf33\u003c/span\u003e\u003cspan address=\"https://iris.who.int/bitstream/handle/10665/365580/WHO-2019-nCoV-clinical-2023.1-eng.pdf33\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhu Q, Wu Y, Mai J, Guo G, Meng J, Fang X et al. Comprehensive Metabolic Profiling of Inflammation Indicated Key Roles of Glycerophospholipid and Arginine Metabolism in Coronary Artery Disease. Front Immunol 2022;13.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCorica B, Tartaglia F, D\u0026rsquo;Amico T, Romiti GF, Cangemi R. Sex and gender differences in community-acquired pneumonia. Intern Emerg Med. 2022;17(6):1575\u0026ndash;88.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZifodya JS, Duncan MS, So-Armah KA, Attia EF, Akg\u0026uuml;n KM, Rodriguez-Barradas MC, et al. Community-acquired pneumonia and risk of cardiovascular events in people living with HIV. J Am Heart Assoc. 2020;9(23):e017645.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDi Mitri C, Arcoleo G, Mazzuca E, Camarda G, Farinella EM, Soresi M, et al. COVID-19 and non\u0026ndash;COVID-19 pneumonia: a comparison. Ann Med. 2021;53(1):2321\u0026ndash;31.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eD\u0026rsquo;ascanio M, Innammorato M, Pasquariello L, Pizzirusso D, Guerrieri G, Castelli S, et al. Age is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes. BMC Geriatr. 2021;21(1):63.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGoldstein JR, Lee RD. Demographic perspectives on the mortality of COVID-19 and other epidemics. Proc Natl Acad Sci U S A 2020;117(36).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCorrection for Goldstein and Lee. Demographic perspectives on the mortality of COVID-19 and other epidemics. Proc Natl Acad Sci. 2020;117(14):22035\u0026ndash;41.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLaxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan CB, Neelima S et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. \u003cem\u003eScience\u003c/em\u003e (1979). 2020;370(6517):691\u0026ndash;697.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDavies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205\u0026ndash;11.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAhmad Malik J, Ahmed S, Shinde M, Almermesh MHS, Alghamdi S, Hussain A, et al. The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It. Saudi J Biol Sci. 2022;29:3586\u0026ndash;99.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRussell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29:334\u0026ndash;43.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKhedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Zein M, Hassany SM et al. Impact of comorbidities on COVID-19 outcome. MedRxiv 2020.11.28.20240267.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020;2(8):e554\u0026ndash;67.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVidal A, Santos L. Comorbidities impact on the prognosis of severe acute community-acquired pneumonia. Porto Biomed J. 2017;2(6):265\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV. 2021;8(9):e554\u0026ndash;67.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022;9:e486\u0026ndash;95.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrown J, Lipman M. Community-acquired pneumonia in HIV-infected individuals. Curr Infect Dis Rep. 2014;16(3):397.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhao H, Yan X, Guo Z, Li K, Wang Z, Wang J, et al. Comparison of outcomes and characteristics of patients admitted to the ICU with COVID-19 and other community-acquired pneumonia based on propensity score matching. BMC Infect Dis. 2024;24(1):419.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen X, Yang Y, Huang M, Liu L, Zhang X, Xu J, et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center. J Med Virol. 2020;92(9):1572\u0026ndash;79.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMondal S, Das TK, Bhattacharya S, Banerjee S, Hazra D. Blood Gas Analysis among COVID-19 Patients: A Single Centre Retrospective Observational Study. J Clin Diagn Res. 2021;15(8):LC01\u0026ndash;04.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSanghani H, Bansal S, Parmar V, Shah R. Study of Arterial Blood Gas Analysis in Moderate-to-Severe COVID-19 Patients. Cureus. 2022;14(7):26715.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWu C, Wang G, Zhang Q, Yu B, Lv J, Zhang S, et al. Association Between Respiratory Alkalosis and the Prognosis of COVID-19 Patients. Front Med (Lausanne). 2021;8:564635.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang WZ. Age-associated increase in creatine kinase-MB-specific activity in human serum confounds its use as an injury marker. Heart Lung Circ. 2005;14(2):104\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBezuidenhout MC, Wiese OJ, Moodley D, Maasdorp E, Davids MR, Koegelenberg CFN, et al. Correlating arterial blood gas, acid\u0026ndash;base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. Ann Clin Biochem. 2021;58(2):95\u0026ndash;101.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang L, Li Y, Zhou J, Li J, Tong C, Cai J, et al. Comparison of the community-acquired pneumonia and COVID-19 at the early stage: Findings from two cohort studies. Ann Palliat Med. 2021;10:9572\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePaliogiannis P, Zinellu A, Scano V, Mulas G, de Riu G, Pascale RM, et al. Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: A preliminary repor\u003cem\u003et\u003c/em\u003e. J Infect Dev Ctries. 2020;14:685\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePan Y, Ye G, Zeng X, Liu G, Zeng X, Jiang X, et al. Can routine laboratory tests discriminate SARS-CoV‐2‐infected pneumonia from other causes of community‐acquired pneumonia? Clin Transl Med. 2020;10:161\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eIepsen UW, Plovsing RR, Tjelle K, Foss NB, Meyhoff CS, Ryrs\u0026oslash; CK et al. The role of lactate in sepsis and COVID-19: Perspective from contracting skeletal muscle metabolism. Exp Physiol 2022;107(7).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNardi G, Sanson G, Tassinari L, Guiotto G, Potalivo A, Montomoli J et al. Lactate Arterial-Central Venous Gradient among COVID-19 Patients in ICU: A Potential Tool in the Clinical Practice. \u003cem\u003eCrit Care Res Pract.\u003c/em\u003e 2020; 2020:4742904.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCarpen\u0026egrave; G, Onorato D, Nocini R, Fortunato G, Rizk JG, Henry BM, et al. Blood lactate concentration in COVID-19: A systematic literature review. Clin Chem Lab Med. 2022;60:332\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFaour WH, Choaib A, Issa E, Choueiry F, El, Shbaklo K, Alhajj M, et al. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. J Inflamm Res. 2022;71:39\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMain C. Acute kidney injury: a COVID-19 update. J Kidney Care. 2021;6(1).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eShafi ST. Covid-19 and Acute Kidney Injury: Recent Updates. Pak J Kidney Dis 2021;4(2).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChegini R, Mojtahedi Z, Lakkakula BV, Pezeshgi A, Niazi S, Nasri H. COVID-19 and the kidney; mechanisms of tubular injury by SARS-CoV-2. J Ren Inj Prev. 2021;10(1):e08.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHirsch JS, Ikizler TA, Sharma S, Mohammed A. Acute Kidney Injury and Advanced Kidney Disease in the COVID-19 Pandemic: Proceedings From a National Kidney Foundation Symposium. \u003cem\u003eKidney Med\u003c/em\u003e. 2021;3(3):426\u0026thinsp;\u0026ndash;\u0026thinsp;32.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNICE guideline. COVID-19 rapid guideline: acute kidney injury in hospital. Nice 2020.Accessed 24 April 2025: https://www.COVID-19 rapid guideline: acute kidney injury in hospital/Guideline/NICE.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVargas JG, Avila N, Hurtado D, C\u0026aacute;rdenas-Rold\u0026aacute;n J, Pe\u0026ntilde;a D, Ortiz G. Acute kidney injury in COVID-19: update and literature review. Acta Colombiana de Cuidado Intensivo. 2022;22(1):24\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKhokhar M, Purohit P, Roy D, Tomo S, Gadwal A, Modi A, et al. Acute kidney injury in COVID 19\u0026ndash;an update on pathophysiology and management modalities. Arch Physiol Biochem. 2023;129(3):636\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNg JH, Bijol V, Sparks MA, Sise ME, Izzedine H, Jhaveri KD. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis. 2020;27(5):365\u0026ndash;76.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBatlle D, Soler MJ, Sparks MA, Hiremath S, South A, Welling P, et al. Acute kidney injury in COVID-19: Emerging evidence of a distinct pathophysiology. J Amer Soc Nephrol. 2020;31:1380\u0026ndash;3.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eUmbro I, Gentile G, Tinti F, Muiesan P, Mitterhofer AP. Recent advances in pathophysiology and biomarkers of sepsis-induced acute kidney injury. J Infect. 2016;72(2):131\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eIzzedine H, Jhaveri KD. Acute kidney injury in patients with COVID-19: an update on the pathophysiology. Nephrol Dial Transpl. 2021;36(2):224\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWang M, Xiong H, Chen H, Li Q, Ruan XZ. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis. 2021;7(2):100\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eXu Z, Tang Y, Huang Q, Fu S, Li X, Lin B, et al. Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. BMC Nephrol. 2021;22(1):52.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829\u0026ndash;38.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Amer Soc Nephrol. 2020;316:1157\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi Z, Wu M, Guo J, Yao J, Liao X, Song S et al. Caution on kidney dysfunctions of 2019-nCoV patients. MedRxiv. 2020.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLippi G, Sanchis-Gomar F, Henry BM, Lavie CJ. Cardiac biomarkers in COVID-19: a narrative review. eJIFCC. 2021;32923:337\u0026ndash;46.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMueller C, Giannitsis E, Jaffe AS, Huber K, Mair J, Cullen L, et al. Cardiovascular biomarkers in patients with COVID-19. Eur Heart J Acute Cardiovasc Care. 2021;10(3):310\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eShi X, Chen M, Zhang Y. The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. Mol Biol Rep. 2021;48(2):310\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi C, Chen H. Unlike common pneumonia, COVID-19 is a risk factor for multiple cardiovascular diseases A two-sample Mendelian randomization study. Medicine (United States). 2024;103:e41015.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eEfros O, Soffer S, Leibowitz A, Fardman A, Klempfner R, Meisel E, et al. Risk factors and mortality in patients with pneumonia and elevated troponin levels. Sci Rep. 2020;10(1):21619.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBorato DCK, Vellosa JCR. Association between soluble biomarkers-microbial translocation, inflammation and cardiovascular risk in HIV-infected individuals: A systematic review. Braz J Pharm Sci. 2020;56:18567.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRobbertse PPS, Doubell AF, Esterhuizen TM, Herbst PG. Antiretroviral therapy and HIV-associated cardiovascular disease: a prospective cardiac biomarker and CMR tissue characterization study. ESC Heart Fail. 2023;11(2):748\u0026ndash;58.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBushaku M, Nyamwange C, Kwena A, Twagirumukiza M, Nepo Utumatwishima J, Mugeni R, et al. Detection of Undiagnosed Elevated Cardiovascular Risk Biomarkers among HIV-Positive Patients on Antiretroviral Therapy (ART) in Kigali-City, Rwanda. J AIDS HIV Treat. 2023;5(1):13\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePiroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251\u0026ndash;59.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDonnino MW, Moskowitz A, Thompson GS, Heydrick SJ, Pawar RD, Berg KM, et al. Comparison between Patients Hospitalized with Influenza and COVID-19 at a Tertiary Care Center. J Gen Intern Med. 2021;36(6):1689\u0026ndash;95.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGonz\u0026aacute;lez-Jim\u0026eacute;nez P, M\u0026eacute;ndez R, Latorre A, Mengot N, Piqueras M, Reyes S, et al. Endothelial Damage, Neutrophil Extracellular Traps and Platelet Activation in COVID-19 vs. Community-Acquired Pneumonia: A Case\u0026ndash;Control Study. Int J Mol Sci. 2023;24(17):13194.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"cardiac biomarkers, cardiovascular events, community-acquired pneumonia, co-morbidities, COVID-19 pneumonia, HIV","lastPublishedDoi":"10.21203/rs.3.rs-7376744/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7376744/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eIntroduction\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere are no studies from sub-Saharan Africa comparing patients with community-acquired pneumonia (CAP) and those with COVID-19 pneumonia, which is what was undertaken in this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConsecutive adult patients hospitalized with CAP (n=59), or COVID-19 pneumonia (n=74) were compared with regard to co-morbidities, HIV status, routine laboratory parameters, and levels of systemic inflammatory and cardiac biomarkers.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere were an equal number of males and females, but CAP patients were younger. Human immunodeficiency virus infection was more common in CAP patients, whereas other comorbidities were more prevalent in COVID-19 pneumonia. CAP patients had more cough, fever, greater tachycardia, and lower blood pressure, while dyspnoea, tachypnoea, and respiratory alkalosis were more prevalent in COVID-19. Several routine laboratory parameters differed. Cardiovascular biomarkers were mostly elevated in both groups compared to controls. However, levels of creatinine kinase-MB (CK-MB) and cardiac troponin I were significantly elevated in COVID-19 versus CAP patients. When compared by HIV status no difference in the cardiac biomarker levels was seen in CAP patients with and without HIV, but significantly higher levels were noted in the HIV-positive COVID-19 group.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCardiac biomarker analysis suggests that HIV-infected patients with COVID-19 pneumonia may be at greatest risk of cardiovascular events.\u003c/p\u003e","manuscriptTitle":"A comparison of clinical and cardiac biomarker profiles of patients with community-acquired pneumonia and with COVID-19 pneumonia in a high HIV prevalence adult population. Running title: Comparison of patients with CAP and COVID-19 pneumonia","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-26 06:24:47","doi":"10.21203/rs.3.rs-7376744/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"def4f621-0534-473b-9f04-1225507f374d","owner":[],"postedDate":"September 26th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-14T15:53:49+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-26 06:24:47","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7376744","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7376744","identity":"rs-7376744","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}